RGD DISEASE ONTOLOGY - ANNOTATIONS |
|
RGD uses the Human Disease Ontology (DO, https://disease-ontology.org/) for disease curation across species. RGD automatically downloads each new release of the ontology on a monthly basis. Some additional terms which are required for RGD's curation purposes but are not currently covered in the official version of DO have been added. As corresponding terms are added to DO, these custom terms are retired and the DO terms substituted in existing annotations and subsequently used for curation.
|
Term: | Neoplastic Processes |
|
Accession: | DOID:9008192
|
browse the term
|
Definition: | The pathological mechanisms and forms taken by tissue during degeneration into a neoplasm and its subsequent activity. |
Synonyms: | primary_id: | MESH:D009385 |
|
|
GViewer not supported for the selected species.
|
|
G |
Chaf1b |
chromatin assembly factor 1 subunit B |
|
ISO |
protein:increased expression:: |
RGD |
PMID:22882088 |
RGD:9587477 |
NCBI chrNW_004624745:27,094,302...27,117,957
Ensembl chrNW_004624745:27,095,361...27,117,669
|
|
G |
Erg |
ETS transcription factor ERG |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27783944 |
|
NCBI chrNW_004624745:25,239,356...25,457,533
Ensembl chrNW_004624745:25,294,832...25,459,683
|
|
G |
Etv1 |
ETS variant transcription factor 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27783944 |
|
NCBI chrNW_004624739:15,943,534...16,031,704
Ensembl chrNW_004624739:15,943,495...16,029,785
|
|
G |
Etv4 |
ETS variant transcription factor 4 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27783944 |
|
NCBI chrNW_004624795:1,079,024...1,090,364
Ensembl chrNW_004624795:1,079,537...1,089,964
|
|
G |
Etv5 |
ETS variant transcription factor 5 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27783944 |
|
NCBI chrNW_004624730:70,631,654...70,699,768
Ensembl chrNW_004624730:70,631,637...70,699,863
|
|
G |
Ewsr1 |
EWS RNA binding protein 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27783944 |
|
NCBI chrNW_004624747:5,647,741...5,676,859
|
|
G |
Hdlbp |
high density lipoprotein binding protein |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:25129143 |
|
NCBI chrNW_004624847:5,278,695...5,341,333
Ensembl chrNW_004624847:5,278,695...5,340,818
|
|
G |
Hoxd9 |
homeobox D9 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26075790 |
|
NCBI chrNW_004624787:13,263,020...13,265,538
Ensembl chrNW_004624787:13,249,946...13,265,627
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:12082015 |
|
NCBI chrNW_004624766:21,907,423...21,913,414
Ensembl chrNW_004624766:21,911,241...21,913,653
|
|
|
G |
Ca9 |
carbonic anhydrase 9 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19808899 |
|
NCBI chrNW_004624868:5,110,602...5,131,167
Ensembl chrNW_004624868:5,109,846...5,116,949
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19808899 |
|
NCBI chrNW_004624734:39,414,458...39,471,705
Ensembl chrNW_004624734:39,411,824...39,471,705
|
|
|
G |
Aicda |
activation induced cytidine deaminase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21570118 |
|
NCBI chrNW_004624860:4,912,938...4,927,846
Ensembl chrNW_004624860:4,912,656...4,926,634
|
|
G |
Bcr |
BCR activator of RhoGEF and GTPase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21570118 |
|
NCBI chrNW_004624747:9,528,968...9,664,055
Ensembl chrNW_004624747:9,528,996...9,662,131
|
|
G |
Esr2 |
estrogen receptor 2 |
|
ISO |
|
RGD |
PMID:12740446 |
RGD:734951 |
NCBI chrNW_004624734:36,742,913...36,862,993
Ensembl chrNW_004624734:36,759,104...36,825,295
|
|
G |
Hmox1 |
heme oxygenase 1 |
|
ISO |
|
RGD |
PMID:22139798 |
RGD:10755566 |
NCBI chrNW_004624750:341,699...346,005
Ensembl chrNW_004624750:342,146...345,887
|
|
G |
Tcn2 |
transcobalamin 2 |
|
ISO |
protein:increased expression:: |
RGD |
PMID:1059479 |
RGD:11060122 |
NCBI chrNW_004624747:6,970,707...6,987,946
Ensembl chrNW_004624747:6,971,289...6,987,440
|
|
|
G |
Alox12 |
arachidonate 12-lipoxygenase, 12S type |
|
ISO |
associated with Prostatic Neoplasms; |
RGD |
PMID:14669797 |
RGD:1578303 |
NCBI chrNW_004624786:9,542,966...9,555,235
Ensembl chrNW_004624786:9,542,970...9,555,214
|
|
G |
Brip1 |
BRCA1 interacting DNA helicase 1 |
|
ISO |
associated with Breast Neoplasms; human gene in a mouse model |
RGD |
PMID:22875853 |
RGD:11252149 |
NCBI chrNW_004624871:2,051,044...2,195,364
Ensembl chrNW_004624871:2,052,863...2,198,165
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
disease_progression |
ISO |
associated with hepatocellular carcinoma;protein:increased expression:liver (human) |
RGD |
PMID:19508713 |
RGD:152023653 |
NCBI chrNW_004624732:35,473,740...35,477,482
Ensembl chrNW_004624732:35,472,760...35,477,528
|
|
G |
Enpp1 |
ectonucleotide pyrophosphatase/phosphodiesterase 1 |
|
ISO |
associated with Breast Neoplasms;mRNA:increased expression:bone element (human) |
RGD |
PMID:23861746 |
RGD:13204736 |
NCBI chrNW_004624753:5,918,005...5,983,480
Ensembl chrNW_004624753:5,917,689...5,982,308
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
|
ISO |
associated with Carcinoma, Renal Cell; mRNA, protein:increased expression:bone (human) |
RGD |
PMID:18709334 |
RGD:2306080 |
NCBI chrNW_004624918:2,228,688...2,239,852
|
|
G |
Pdgfd |
platelet derived growth factor D |
|
ISO |
associated with prostate carcinoma |
RGD |
PMID:22158043 |
RGD:13506772 |
NCBI chrNW_004624918:1,052,640...1,293,138
Ensembl chrNW_004624918:1,052,567...1,293,192
|
|
|
G |
Abl1 |
ABL proto-oncogene 1, non-receptor tyrosine kinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:23968727 |
|
NCBI chrNW_004624760:4,878,811...5,032,719
Ensembl chrNW_004624760:4,878,556...5,031,491
|
|
G |
Adprh |
ADP-ribosylarginine hydrolase |
|
ISO |
|
RGD |
PMID:21697277 |
RGD:13838723 |
NCBI chrNW_004624731:28,611,995...28,620,699
Ensembl chrNW_004624731:28,613,773...28,620,489
|
|
G |
Akr1a1 |
aldo-keto reductase family 1 member A1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:32805337 |
|
NCBI chrNW_004624906:1,463,201...1,474,001
Ensembl chrNW_004624906:1,462,693...1,474,214
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:32045588 |
|
NCBI chrNW_004624734:507,880...525,295
Ensembl chrNW_004624734:509,368...525,295
|
|
G |
Braf |
B-Raf proto-oncogene, serine/threonine kinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:24717435 |
|
NCBI chrNW_004624765:20,766,368...20,951,560
Ensembl chrNW_004624765:20,773,885...20,951,736
|
|
G |
Cav1 |
caveolin 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:29247004 |
|
NCBI chrNW_004624827:2,844,855...2,878,367
Ensembl chrNW_004624827:2,844,115...2,879,179
|
|
G |
Cux1 |
cut like homeobox 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:24316979 |
|
NCBI chrNW_004624740:15,289,616...15,664,090
Ensembl chrNW_004624740:15,287,421...15,664,077
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
disease_progression |
ISO |
|
RGD |
PMID:21163286 |
RGD:9588222 |
NCBI chrNW_004624828:2,316,042...2,358,866
Ensembl chrNW_004624828:2,315,251...2,358,711
|
|
G |
Dnmt3a |
DNA methyltransferase 3 alpha |
disease_progression |
ISO |
|
RGD |
PMID:21163286 |
RGD:9588222 |
NCBI chrNW_004624738:7,481,084...7,581,332
Ensembl chrNW_004624738:7,485,842...7,581,056
|
|
G |
Epas1 |
endothelial PAS domain protein 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26735578 |
|
NCBI chrNW_004624738:27,747,770...27,831,213
Ensembl chrNW_004624738:27,747,696...27,834,054
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:25221644 |
|
NCBI chrNW_004624795:3,373,313...3,391,509
Ensembl chrNW_004624795:3,373,000...3,391,602
|
|
G |
Gata3 |
GATA binding protein 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:35115686 |
|
NCBI chrNW_004624775:2,985,077...3,014,567
Ensembl chrNW_004624775:2,994,164...3,015,392
|
|
G |
Isg15 |
ISG15 ubiquitin like modifier |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:35506701 |
|
NCBI chrNW_004624818:8,510,657...8,511,749
|
|
G |
Kras |
KRAS proto-oncogene, GTPase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26595770 PMID:29247004 |
|
NCBI chrNW_004624752:13,809,741...13,847,020
Ensembl chrNW_004624752:13,809,775...13,844,166
|
|
G |
Map3k8 |
mitogen-activated protein kinase kinase kinase 8 |
|
ISO |
|
RGD |
PMID:15287022 PMID:23533274 |
RGD:151356924 RGD:151356978 |
NCBI chrNW_004624805:2,611,297...2,633,650
Ensembl chrNW_004624805:2,611,038...2,633,943
|
|
G |
Met |
MET proto-oncogene, receptor tyrosine kinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:32045588 |
|
NCBI chrNW_004624827:2,589,157...2,724,065
Ensembl chrNW_004624827:2,587,966...2,723,995
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:29228771 |
|
NCBI chrNW_004624787:14,355,330...14,381,353
Ensembl chrNW_004624787:14,355,791...14,381,251
|
|
G |
Pafah1b1 |
platelet activating factor acetylhydrolase 1b regulatory subunit 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:24487275 |
|
NCBI chrNW_004624786:5,223,890...5,306,033
Ensembl chrNW_004624786:5,224,982...5,302,436
|
|
G |
Pou5f1 |
POU class 5 homeobox 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:35506701 |
|
NCBI chrNW_004624754:24,758,055...24,764,723
|
|
G |
Sparc |
secreted protein acidic and cysteine rich |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26783756 |
|
NCBI chrNW_004624733:37,348,993...37,369,804
Ensembl chrNW_004624733:37,338,284...37,369,804
|
|
G |
Tnfsf8 |
TNF superfamily member 8 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:11552987 |
|
NCBI chrNW_004624760:20,251,390...20,280,358
Ensembl chrNW_004624760:20,253,437...20,280,522
|
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:29044505 |
|
NCBI chrNW_004624795:3,373,313...3,391,509
Ensembl chrNW_004624795:3,373,000...3,391,602
|
|
|
G |
Ace |
angiotensin I converting enzyme |
|
ISO |
associated with colorectal cancer;mRNA:increased expression:liver (mouse) |
RGD |
PMID:20380732 |
RGD:25671446 |
NCBI chrNW_004624849:998,262...1,019,305
Ensembl chrNW_004624849:998,277...1,019,521
|
|
G |
Braf |
B-Raf proto-oncogene, serine/threonine kinase |
severity |
ISO |
associated with skin melanoma;DNA:missense mutations:cds: associated with colorectal cancer;DNA:missense mutation:cds:p.V600E (human) associated with colorectal cancer;DNA:mutations:multiple associated with colorectal cancer;DNA:mutation:cds: associated with colorectal cancer;DNA:missense mutations:cds:pV599E,p.V600E (human) |
RGD |
PMID:22331825 PMID:23010994 PMID:26775732 PMID:27737491 PMID:28787433 |
RGD:11554843 RGD:14696791 RGD:15039394 RGD:18337264 RGD:18337265 |
NCBI chrNW_004624765:20,766,368...20,951,560
Ensembl chrNW_004624765:20,773,885...20,951,736
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
treatment |
ISO |
associated with Animal Mammary Neoplasms; |
RGD |
PMID:15692764 |
RGD:14995455 |
NCBI chrNW_004624875:3,334,136...3,342,085
Ensembl chrNW_004624875:3,334,078...3,341,614
|
|
G |
Ccnd2 |
cyclin D2 |
|
ISO |
associated with colorectal cancer;protein:increased expression:colorectum |
RGD |
PMID:19508551 |
RGD:151665111 |
NCBI chrNW_004624860:1,383,015...1,405,107
Ensembl chrNW_004624860:1,382,948...1,405,107
|
|
G |
Ccng1 |
cyclin G1 |
treatment |
ISO |
human cells in mouse model |
RGD |
PMID:10910035 |
RGD:151356987 |
NCBI chrNW_004624733:26,366,448...26,378,062
Ensembl chrNW_004624733:26,367,200...26,376,664
|
|
G |
Cd44 |
CD44 molecule (IN blood group) |
|
ISO |
associated with Breast Neoplasm;protein:increased expression:liver |
RGD |
PMID:17991717 |
RGD:2289349 |
NCBI chrNW_004624767:11,938,452...12,024,970
Ensembl chrNW_004624767:11,938,028...12,025,069
|
|
G |
Chd4 |
chromodomain helicase DNA binding protein 4 |
ameliorates |
ISO |
associated with human colon adenocarcinoma cells in a mouse model |
RGD |
PMID:28486105 |
RGD:153323299 |
NCBI chrNW_004624860:3,285,086...3,318,939
Ensembl chrNW_004624860:3,283,837...3,318,985
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
treatment |
ISO |
associated with colon carcinoma; |
RGD |
PMID:30381616 |
RGD:27095891 |
NCBI chrNW_004624757:14,989,241...14,991,650
Ensembl chrNW_004624757:14,989,084...14,991,910
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
ameliorates |
ISO |
associated with colorectal cancer; human cells in mouse model |
RGD |
PMID:30789971 |
RGD:151893289 |
NCBI chrNW_004624922:1,261,228...1,273,755
Ensembl chrNW_004624922:1,261,228...1,273,758
|
|
G |
Cxcl8 |
C-X-C motif chemokine ligand 8 |
|
ISO |
associated with colorectal cancer; human colon adenocarcinoma cells in a mouse model |
RGD |
PMID:29679563 |
RGD:26884358 |
NCBI chrNW_004624730:1,744,097...1,747,206
Ensembl chrNW_004624730:1,743,916...1,747,293
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
ameliorates |
ISO |
human cells in mouse model; associated with colorectal cancer associated with colorectal cancer; human cells in mouse model |
RGD |
PMID:29436696 PMID:30789971 |
RGD:151893289 RGD:152023643 |
NCBI chrNW_004624732:35,473,740...35,477,482
Ensembl chrNW_004624732:35,472,760...35,477,528
|
|
G |
Daxx |
death domain associated protein |
exacerbates |
ISO |
associated with neuroendocrine tumor;DNA:mutations:CDS:multiple (human) associated with colon cancer; mRNA:decreased expression:liver (human) associated with pancreatic endocrine carcinoma;DNA:mutations:CDS:multiple (human) |
RGD |
PMID:30339629 PMID:30342802 PMID:31942198 |
RGD:152025194 RGD:152025199 RGD:152025203 |
NCBI chrNW_004624754:23,504,465...23,509,034
Ensembl chrNW_004624754:23,505,386...23,509,241
|
|
G |
Ddr1 |
discoidin domain receptor tyrosine kinase 1 |
treatment |
ISO |
human cells in mouse model; nilotinib mRNA:increased expression:liver (mouse) |
RGD |
PMID:29438985 PMID:30666650 PMID:33110221 |
RGD:151347537 RGD:151347685 RGD:151347840 |
NCBI chrNW_004624754:24,881,439...24,905,633
Ensembl chrNW_004624754:24,880,496...24,896,995
|
|
G |
Ddr2 |
discoidin domain receptor tyrosine kinase 2 |
ameliorates |
ISO |
associated with colon carcinoma associated with melanoma; |
RGD |
PMID:21701781 PMID:22071959 |
RGD:150429701 RGD:150429713 |
NCBI chrNW_004624826:1,225,217...1,255,889
Ensembl chrNW_004624826:1,173,621...1,249,692
|
|
G |
Dock6 |
dedicator of cytokinesis 6 |
ameliorates |
ISO |
associated with stomach cancer; |
RGD |
PMID:29587866 |
RGD:155791564 |
NCBI chrNW_004624828:3,063,094...3,110,603
Ensembl chrNW_004624828:3,063,281...3,110,541
|
|
G |
Fbxw7 |
F-box and WD repeat domain containing 7 |
disease_progression |
ISO |
associated with colorectal cancer; |
RGD |
PMID:28846828 |
RGD:21408566 |
NCBI chrNW_004624858:3,778,842...3,974,351
Ensembl chrNW_004624858:3,775,795...3,873,336
|
|
G |
Fgfr1 |
fibroblast growth factor receptor 1 |
|
ISO |
associated with colorectal cancer;mRNA:increased expression:colorectal mucosa: |
RGD |
PMID:19082464 |
RGD:25330357 |
NCBI chrNW_004624780:5,161,245...5,212,641
Ensembl chrNW_004624780:5,161,073...5,213,870
|
|
G |
Fosl2 |
FOS like 2, AP-1 transcription factor subunit |
|
ISO |
human cells in mouse model |
RGD |
PMID:30114390 |
RGD:153344554 |
NCBI chrNW_004624738:10,370,479...10,391,623
Ensembl chrNW_004624738:10,370,103...10,391,623
|
|
G |
Gpc3 |
glypican 3 |
|
ISO |
protein:increased expression:blood serum (human) |
RGD |
PMID:28801286 |
RGD:243065135 |
NCBI chrNW_004624797:13,234,741...13,678,542
Ensembl chrNW_004624797:13,230,932...13,678,742
|
|
G |
Hmbs |
hydroxymethylbilane synthase |
|
ISO |
associated with colon adenocarcinoma;protein:decreased activity:liver(rat) |
RGD |
PMID:1386052 |
RGD:25440496 |
NCBI chrNW_004624784:14,467,515...14,474,954
Ensembl chrNW_004624784:14,467,533...14,474,954
|
|
G |
Il2 |
interleukin 2 |
treatment |
ISO |
associated with Colorectal Neoplasms, Carcinoma, Hepatocellular; associated with colon carcinoma |
RGD |
PMID:9354462 PMID:11591892 |
RGD:14928215 RGD:8663446 |
NCBI chrNW_004624777:2,885,537...2,890,453
Ensembl chrNW_004624777:2,885,535...2,890,453
|
|
G |
Map2k7 |
mitogen-activated protein kinase kinase 7 |
|
ISO |
associated with colon cancer;protein:increased expression:colon (human) |
RGD |
PMID:24533778 |
RGD:155259116 |
NCBI chrNW_004624828:869,424...878,358
Ensembl chrNW_004624828:869,425...878,231
|
|
G |
Mpl |
MPL proto-oncogene, thrombopoietin receptor |
severity exacerbates |
ISO |
associated with colorectal carcinoma;protein:increased expression:colorectum (human) associated with pancreatic ductal adenocarcinoma; human cells in mouse model associated with pancreatic cancer; protein:increased expression:liver, pancreas (human) |
RGD |
PMID:23747337 PMID:30770989 |
RGD:126925751 RGD:126925752 |
NCBI chrNW_004624892:2,656,260...2,671,455
Ensembl chrNW_004624892:2,656,260...2,669,946
|
|
G |
Nras |
NRAS proto-oncogene, GTPase |
susceptibility |
ISO |
associated with colorectal cancer;DNA:mutations:exons (human) human gene in a mouse model;DNA:missense mutations:cds:p.G12V, p.Q61K (human) associated with melanoma;DNA:mutations: exons (human) |
RGD |
PMID:26799184 PMID:28011498 PMID:28787433 |
RGD:14696774 RGD:14696791 RGD:14696792 |
NCBI chrNW_004624772:10,358,554...10,369,371
|
|
G |
Ptprb |
protein tyrosine phosphatase receptor type B |
treatment |
ISO |
mouse tumor cells in mouse recipient |
RGD |
PMID:31348125 |
RGD:151660353 |
NCBI chrNW_004624750:27,188,858...27,320,470
Ensembl chrNW_004624750:27,188,729...27,316,150
|
|
G |
Rictor |
RPTOR independent companion of MTOR complex 2 |
disease_progression |
ISO |
mRNA:increased expression:liver (human) |
RGD |
PMID:30404068 |
RGD:152995463 |
NCBI chrNW_004624759:15,837,027...15,973,248
Ensembl chrNW_004624759:15,837,064...15,968,894
|
|
G |
Rnf43 |
ring finger protein 43 |
|
ISO |
associated with colorectal adenocarcinoma;mRNA:increased expression:liver (human) |
RGD |
PMID:28789449 |
RGD:151361221 |
NCBI chrNW_004624871:191,534...259,134
Ensembl chrNW_004624871:191,546...259,120
|
|
G |
Slc3a2 |
solute carrier family 3 member 2 |
severity |
ISO |
associated with colon adenocarcinoma |
RGD |
PMID:11745822 |
RGD:151361130 |
NCBI chrNW_004624926:1,301,866...1,314,598
Ensembl chrNW_004624926:1,301,584...1,315,707
|
|
G |
Slc7a5 |
solute carrier family 7 member 5 |
severity |
ISO |
associated with colon cancer associated with colon adenocarcinoma |
RGD |
PMID:11718450 PMID:11745822 |
RGD:151361129 RGD:151361130 |
NCBI chrNW_004624746:1,325,368...1,349,616
|
|
G |
Smad4 |
SMAD family member 4 |
treatment |
ISO |
associated with colorectal carcinoma;protein:decreased expression:colorectum: associated with colorectal carcinoma; DNA:mutations: : |
RGD |
PMID:17390050 PMID:29551247 |
RGD:18937000 RGD:21066338 |
NCBI chrNW_004624778:14,570,025...14,629,950
Ensembl chrNW_004624778:14,570,348...14,630,325
|
|
G |
Sox30 |
SRY-box transcription factor 30 |
ameliorates |
ISO |
|
RGD |
PMID:29739711 |
RGD:151660333 |
NCBI chrNW_004624733:31,774,341...31,855,539
Ensembl chrNW_004624733:31,774,616...31,807,516
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
disease_progression |
ISO |
associated with colon cancer;protein:increased activity:colon |
RGD |
PMID:7678609 |
RGD:150521542 |
NCBI chrNW_004624842:2,212,561...2,260,514
Ensembl chrNW_004624842:2,211,020...2,230,132
|
|
G |
Vegfa |
vascular endothelial growth factor A |
|
ISO |
associated with colorectal carcinoma;mRNA,protein:increased expression:liver: |
RGD |
PMID:22156924 |
RGD:15014782 |
NCBI chrNW_004624754:15,929,414...15,943,637
|
|
|
G |
Adam28 |
ADAM metallopeptidase domain 28 |
ameliorates |
ISO |
associated with lung carcinoma, breast carcinoma associated with lung adenocarcinoma; |
RGD |
PMID:22636800 PMID:26800504 |
RGD:11531771 RGD:153297785 |
NCBI chrNW_004624758:19,427,871...19,499,510
Ensembl chrNW_004624758:19,432,817...19,497,686
|
|
G |
Arhgap5 |
Rho GTPase activating protein 5 |
|
ISO |
associated with Mammary Neoplasms, Experimental |
RGD |
PMID:20860838 |
RGD:126848767 |
NCBI chrNW_004624820:302,000...381,043
Ensembl chrNW_004624820:305,475...381,058
|
|
G |
Arid2 |
AT-rich interaction domain 2 |
exacerbates |
ISO |
associated with hepatocellular carcinoma, |
RGD |
PMID:32071245 |
RGD:150340708 |
NCBI chrNW_004624816:6,329,888...6,521,535
Ensembl chrNW_004624816:6,332,612...6,521,535
|
|
G |
Azgp1 |
alpha-2-glycoprotein 1, zinc-binding |
ameliorates |
ISO |
associated with hepatocellular carcinoma; |
RGD |
PMID:26902423 PMID:27993894 |
RGD:153350132 RGD:153350133 |
NCBI chrNW_004624740:17,054,221...17,062,420
Ensembl chrNW_004624740:17,054,221...17,063,226
|
|
G |
Ca12 |
carbonic anhydrase 12 |
ameliorates |
ISO |
associated with breast cancer; |
RGD |
PMID:29786141 |
RGD:155226861 |
NCBI chrNW_004624781:9,140,753...9,195,651
Ensembl chrNW_004624781:9,140,837...9,196,400
|
|
G |
Cblb |
Cbl proto-oncogene B |
severity |
ISO |
associated with stomach carcinoma; |
RGD |
PMID:28334634 |
RGD:150540337 |
NCBI chrNW_004624731:43,803,743...44,018,682
Ensembl chrNW_004624731:43,803,768...44,015,870
|
|
G |
Ccng1 |
cyclin G1 |
|
ISO |
|
RGD |
PMID:30565428 |
RGD:151361205 |
NCBI chrNW_004624733:26,366,448...26,378,062
Ensembl chrNW_004624733:26,367,200...26,376,664
|
|
G |
Chd4 |
chromodomain helicase DNA binding protein 4 |
ameliorates |
ISO |
associated with human colon adenocarcinoma cells in a mouse model |
RGD |
PMID:28486105 |
RGD:153323299 |
NCBI chrNW_004624860:3,285,086...3,318,939
Ensembl chrNW_004624860:3,283,837...3,318,985
|
|
G |
Col10a1 |
collagen type X alpha 1 chain |
ameliorates |
ISO |
associated with H1299 cell |
RGD |
PMID:33324550 |
RGD:150429752 |
NCBI chrNW_004624856:2,366,524...2,372,928
Ensembl chrNW_004624856:2,335,986...2,372,848
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
ameliorates |
ISO |
associated with colorectal cancer; human cells in mouse model associated with nasopharynx carcinoma; human cells in mouse model associated with osteosarcoma and melanoma |
RGD |
PMID:16000558 PMID:18071913 PMID:26498029 PMID:31938138 |
RGD:151665329 RGD:151893515 RGD:152023752 RGD:152177473 |
NCBI chrNW_004624732:35,473,740...35,477,482
Ensembl chrNW_004624732:35,472,760...35,477,528
|
|
G |
Ddr1 |
discoidin domain receptor tyrosine kinase 1 |
|
ISO |
|
RGD |
PMID:29483153 |
RGD:151347599 |
NCBI chrNW_004624754:24,881,439...24,905,633
Ensembl chrNW_004624754:24,880,496...24,896,995
|
|
G |
Ddr2 |
discoidin domain receptor tyrosine kinase 2 |
exacerbates |
ISO |
associated with tongue squamous cell carcinoma; |
RGD |
PMID:24556606 |
RGD:150429746 |
NCBI chrNW_004624826:1,225,217...1,255,889
Ensembl chrNW_004624826:1,173,621...1,249,692
|
|
G |
Fasn |
fatty acid synthase |
|
ISO |
associated with head and neck squamous cell carcinoma |
RGD |
PMID:20604875 |
RGD:126790467 |
NCBI chrNW_004624801:10,910,022...10,926,505
Ensembl chrNW_004624801:10,909,647...10,927,547
|
|
G |
Fosl2 |
FOS like 2, AP-1 transcription factor subunit |
|
ISO |
human cells in mouse model |
RGD |
PMID:30326930 |
RGD:153344557 |
NCBI chrNW_004624738:10,370,479...10,391,623
Ensembl chrNW_004624738:10,370,103...10,391,623
|
|
G |
Hilpda |
hypoxia inducible lipid droplet associated |
|
ISO |
human cells in mouse model |
RGD |
PMID:31142329 |
RGD:153344574 |
NCBI chrNW_004624783:7,536,257...7,538,380
Ensembl chrNW_004624783:7,536,167...7,538,418
|
|
G |
Itgav |
integrin subunit alpha V |
treatment |
ISO |
human cells in rat model |
RGD |
PMID:20841470 |
RGD:152998949 |
NCBI chrNW_004624899:3,235,434...3,292,584
Ensembl chrNW_004624899:3,239,112...3,291,586
|
|
G |
Map3k1 |
mitogen-activated protein kinase kinase kinase 1 |
ameliorates |
ISO |
associated with breast carcinoma |
RGD |
PMID:16568086 |
RGD:150573808 |
NCBI chrNW_004624759:2,360,655...2,429,189
Ensembl chrNW_004624759:2,363,076...2,428,273
|
|
G |
Map3k8 |
mitogen-activated protein kinase kinase kinase 8 |
ameliorates |
ISO |
associated with clear cell renal cell carcinoma |
RGD |
PMID:23982215 |
RGD:151356974 |
NCBI chrNW_004624805:2,611,297...2,633,650
Ensembl chrNW_004624805:2,611,038...2,633,943
|
|
G |
Nf2 |
NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor |
|
ISO |
associated with hepatocellular carcinoma |
RGD |
PMID:26443326 |
RGD:11076529 |
NCBI chrNW_004624747:5,923,827...6,011,276
Ensembl chrNW_004624747:5,923,834...6,011,939
|
|
G |
Ntrk3 |
neurotrophic receptor tyrosine kinase 3 |
ameliorates |
ISO |
associated with mammary carcinoma |
RGD |
PMID:20802235 |
RGD:150520014 |
NCBI chrNW_004624768:15,239,111...15,619,979
Ensembl chrNW_004624768:15,252,354...15,619,601
|
|
G |
Pagr1 |
PAXIP1 associated glutamate rich protein 1 |
|
ISO |
human cells in mouse model |
RGD |
PMID:33833989 |
RGD:153344568 |
NCBI chrNW_004624782:13,387,155...13,390,153
Ensembl chrNW_004624782:13,387,376...13,389,740
|
|
G |
Ptprb |
protein tyrosine phosphatase receptor type B |
treatment |
ISO |
|
RGD |
PMID:23899555 |
RGD:151660352 |
NCBI chrNW_004624750:27,188,858...27,320,470
Ensembl chrNW_004624750:27,188,729...27,316,150
|
|
G |
Rictor |
RPTOR independent companion of MTOR complex 2 |
|
ISO |
human cells in mouse model |
RGD |
PMID:20978191 PMID:29809146 |
RGD:152995469 RGD:152995516 |
NCBI chrNW_004624759:15,837,027...15,973,248
Ensembl chrNW_004624759:15,837,064...15,968,894
|
|
G |
Rptor |
regulatory associated protein of MTOR complex 1 |
|
ISO |
|
RGD |
PMID:29809146 |
RGD:152995516 |
NCBI chrNW_004624801:9,676,965...10,053,311
Ensembl chrNW_004624801:9,677,307...10,048,719
|
|
G |
Sf3b4 |
splicing factor 3b subunit 4 |
|
ISO |
human cells in mouse model |
RGD |
PMID:30391496 |
RGD:155804298 |
NCBI chrNW_004624772:17,701,930...17,706,613
Ensembl chrNW_004624772:17,701,341...17,706,550
|
|
G |
Sox30 |
SRY-box transcription factor 30 |
ameliorates |
ISO |
|
RGD |
PMID:29739711 |
RGD:151660333 |
NCBI chrNW_004624733:31,774,341...31,855,539
Ensembl chrNW_004624733:31,774,616...31,807,516
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
treatment ameliorates |
ISO |
associated with breast cancer; associated with nasopharynx carcinoma; |
RGD |
PMID:15753384 PMID:27078847 |
RGD:150521726 RGD:1581400 |
NCBI chrNW_004624842:2,212,561...2,260,514
Ensembl chrNW_004624842:2,211,020...2,230,132
|
|
|
G |
Abca13 |
ATP binding cassette subfamily A member 13 |
susceptibility |
ISO |
DNA:amplification:cds: (human, male) |
RGD |
PMID:27366209 |
RGD:152995256 |
NCBI chrNW_004624740:5,112,422...5,488,394
Ensembl chrNW_004624740:5,114,019...5,488,385
|
|
G |
Adam28 |
ADAM metallopeptidase domain 28 |
|
ISO |
associated with breast cancer;DNA:hypermethylation: |
RGD |
PMID:25620615 |
RGD:153298970 |
NCBI chrNW_004624758:19,427,871...19,499,510
Ensembl chrNW_004624758:19,432,817...19,497,686
|
|
G |
Adgrb1 |
adhesion G protein-coupled receptor B1 |
disease_progression |
ISO |
associated with stomach cancer; |
RGD |
PMID:11172604 |
RGD:13831357 |
NCBI chrNW_004624735:14,049,621...14,126,287
Ensembl chrNW_004624735:14,050,213...14,113,534
|
|
G |
Aicda |
activation induced cytidine deaminase |
|
ISO |
associated with stomach cancer;protein:increased expression:stomach (human) |
RGD |
PMID:21538122 |
RGD:127285638 |
NCBI chrNW_004624860:4,912,938...4,927,846
Ensembl chrNW_004624860:4,912,656...4,926,634
|
|
G |
Angptl4 |
angiopoietin like 4 |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:17130448 |
|
NCBI chrNW_004624828:1,152,788...1,158,864
Ensembl chrNW_004624828:1,152,891...1,158,420
|
|
G |
Anxa1 |
annexin A1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19381893 |
|
NCBI chrNW_004624811:765,338...782,203
Ensembl chrNW_004624811:764,940...782,198
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21401805 |
|
NCBI chrNW_004624736:38,194,722...38,200,961
Ensembl chrNW_004624736:38,194,545...38,201,036
|
|
G |
Arhgap5 |
Rho GTPase activating protein 5 |
|
ISO |
associated with nasopharynx carcinoma;mRNA, protein:increased expression: epithelium of nasopharynx |
RGD |
PMID:25961434 |
RGD:11056278 |
NCBI chrNW_004624820:302,000...381,043
Ensembl chrNW_004624820:305,475...381,058
|
|
G |
Asxl1 |
ASXL transcriptional regulator 1 |
|
ISO |
associated with colorectal cancer |
RGD |
PMID:32317519 |
RGD:126779580 |
NCBI chrNW_004624741:188,985...258,065
Ensembl chrNW_004624741:188,745...250,142
|
|
G |
Axl |
AXL receptor tyrosine kinase |
|
ISO |
associated Pancreatic Neoplasms |
RGD |
PMID:19252414 |
RGD:2325833 |
NCBI chrNW_004624907:76,236...106,765
Ensembl chrNW_004624907:77,806...106,228
|
|
G |
Bag1 |
BAG cochaperone 1 |
disease_progression |
ISO |
associated with Breast Neoplasms:protein:increased expression:breast |
RGD |
PMID:18430249 |
RGD:2292908 |
NCBI chrNW_004624736:38,015,150...38,025,079
Ensembl chrNW_004624736:38,015,044...38,025,079
|
|
G |
Bambi |
BMP and activin membrane bound inhibitor |
|
ISO |
associated with stomach cancer; protein:increased expression: : |
RGD |
PMID:24752577 |
RGD:14390158 |
NCBI chrNW_004624805:1,967,174...1,973,030
Ensembl chrNW_004624805:1,967,101...1,974,898
|
|
G |
Barhl2 |
BarH like homeobox 2 |
|
ISO |
associated with oral squamous cell carcinoma; mRNA:decreased expression:mouth mucosa |
RGD |
PMID:27542258 |
RGD:14390167 |
NCBI chrNW_004624742:7,027,122...7,033,342
Ensembl chrNW_004624742:7,027,069...7,034,308
|
|
G |
Bcl2 |
BCL2 apoptosis regulator |
|
ISO |
associated with Breast Neoplasms;protein:increased expression:lymph node |
RGD |
PMID:18217456 |
RGD:2293013 |
NCBI chrNW_004624792:8,854,345...9,032,727
Ensembl chrNW_004624792:8,859,522...9,031,344
|
|
G |
Bik |
BCL2 interacting killer |
|
ISO |
associated with cholangiocarcinoma;DNA:CNV:: |
RGD |
PMID:16865775 |
RGD:14394820 |
NCBI chrNW_004624752:5,839,422...5,856,350
|
|
G |
Birc5 |
baculoviral IAP repeat containing 5 |
disease_progression |
ISO |
associated with Cervix Neoplasms;mRNA:splice variant associated with Breast Neoplasms |
RGD |
PMID:17285241 PMID:17877643 |
RGD:2293098 RGD:2293103 |
NCBI chrNW_004624801:7,727,084...7,735,946
Ensembl chrNW_004624801:7,727,093...7,735,940
|
|
G |
Braf |
B-Raf proto-oncogene, serine/threonine kinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:29426936 |
|
NCBI chrNW_004624765:20,766,368...20,951,560
Ensembl chrNW_004624765:20,773,885...20,951,736
|
|
G |
Brd7 |
bromodomain containing 7 |
severity |
ISO |
protein:increased expression:lung: |
RGD |
PMID:22008115 |
RGD:9586442 |
NCBI chrNW_004624757:6,294,559...6,335,401
Ensembl chrNW_004624757:6,294,415...6,335,285
|
|
G |
Bsg |
basigin (Ok blood group) |
disease_progression |
ISO |
associated with Breast Neoplasms |
RGD |
PMID:16004819 |
RGD:2289055 |
NCBI chrNW_004624828:7,913,297...7,920,891
Ensembl chrNW_004624828:7,913,099...7,920,804
|
|
G |
Btk |
Bruton tyrosine kinase |
disease_progression |
ISO |
associated with lung adenocarcinoma;protein:increased expression:lung (human) |
RGD |
PMID:31200752 |
RGD:151347847 |
NCBI chrNW_004624902:1,173,101...1,216,662
Ensembl chrNW_004624902:1,182,682...1,216,171
|
|
G |
Ca9 |
carbonic anhydrase 9 |
|
ISO |
associated with Cervix Neoplasms |
RGD |
PMID:17233814 |
RGD:2293196 |
NCBI chrNW_004624868:5,110,602...5,131,167
Ensembl chrNW_004624868:5,109,846...5,116,949
|
|
G |
Cab39 |
calcium binding protein 39 |
|
ISO |
associated with pancreatic cancer;RNA:increased expression:pancreas |
RGD |
PMID:28197410 |
RGD:14398834 |
NCBI chrNW_004624843:4,129,755...4,217,406
Ensembl chrNW_004624843:4,130,052...4,217,540
|
|
G |
Casp9 |
caspase 9 |
|
ISO |
associated with Carcinoma, Non-Small-Cell Lung;DNA:SNP:exon:rs1052576 (human) |
RGD |
PMID:17285546 |
RGD:13434907 |
NCBI chrNW_004624764:1,769,270...1,789,399
Ensembl chrNW_004624764:1,773,455...1,789,423
|
|
G |
Cav1 |
caveolin 1 |
disease_progression |
ISO |
associated with Melanoma |
RGD |
PMID:22134245 |
RGD:8661767 |
NCBI chrNW_004624827:2,844,855...2,878,367
Ensembl chrNW_004624827:2,844,115...2,879,179
|
|
G |
Cbl |
Cbl proto-oncogene |
|
ISO |
associated with stomach carcinoma;protein:increased expression:stomach |
RGD |
PMID:31611438 |
RGD:126925223 |
NCBI chrNW_004624784:14,577,582...14,671,816
Ensembl chrNW_004624784:14,577,515...14,667,575
|
|
G |
Cblb |
Cbl proto-oncogene B |
|
ISO |
associated with stomach carcinoma; |
RGD |
PMID:20038312 |
RGD:150540338 |
NCBI chrNW_004624731:43,803,743...44,018,682
Ensembl chrNW_004624731:43,803,768...44,015,870
|
|
G |
Ccnd2 |
cyclin D2 |
|
ISO |
associated with colorectal cancer;protein:increased expression:colorectum |
RGD |
PMID:19508551 |
RGD:151665111 |
NCBI chrNW_004624860:1,383,015...1,405,107
Ensembl chrNW_004624860:1,382,948...1,405,107
|
|
G |
Ccne1 |
cyclin E1 |
|
ISO |
associated with Carcinoma, Transitional Cell;protein:decreased expression |
RGD |
PMID:16949911 |
RGD:2289266 |
NCBI chrNW_004624794:4,957,156...4,967,058
Ensembl chrNW_004624794:4,957,178...4,967,140
|
|
G |
Ccnh |
cyclin H |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:30705370 |
|
NCBI chrNW_004624743:6,883,124...6,902,518
Ensembl chrNW_004624743:6,883,114...6,902,745
|
|
G |
Cd274 |
CD274 molecule |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:16530813 |
|
NCBI chrNW_004624736:9,991,851...10,017,047
Ensembl chrNW_004624736:9,996,156...10,013,814
|
|
G |
Cd40 |
CD40 molecule |
|
ISO |
associated with breast cancer;DNA:snps:5' utr, intron:c.-1T>C, c.51+914T>G (rs1883832, rs4810485) (human) |
RGD |
PMID:21912605 |
RGD:8547780 |
NCBI chrNW_004624790:8,475,640...8,485,927
Ensembl chrNW_004624790:8,476,158...8,485,856
|
|
G |
Cd44 |
CD44 molecule (IN blood group) |
|
ISO |
associated with Breast Neoplasms, Colorectal Neoplasms, Stomach Neoplasms;mRNA, protein:splice variant, increased expression:breast, large intestine, stomach |
RGD |
PMID:16425351 |
RGD:2289356 |
NCBI chrNW_004624767:11,938,452...12,024,970
Ensembl chrNW_004624767:11,938,028...12,025,069
|
|
G |
Cdh1 |
cadherin 1 |
|
ISO |
associated with Cervix Neoplasms associated with Breast Neoplasms |
RGD |
PMID:17649807 PMID:18097581 |
RGD:2289498 RGD:2296046 |
NCBI chrNW_004624746:17,480,472...17,557,722
Ensembl chrNW_004624746:17,483,469...17,557,581
|
|
G |
Cdkn1a |
cyclin dependent kinase inhibitor 1A |
|
ISO |
associated with Eyelid Neoplasms; associated with Oral Squamous Cell Carcinoma; |
RGD |
PMID:15817070 PMID:19628749 |
RGD:8661799 RGD:8662374 |
NCBI chrNW_004624754:21,109,074...21,115,869
Ensembl chrNW_004624754:21,108,874...21,115,885
|
|
G |
Cdkn1b |
cyclin dependent kinase inhibitor 1B |
|
ISO |
associated with non-small cell lung carcinoma associated with Breast Neoplasms |
RGD |
PMID:12015771 PMID:28601655 |
RGD:13673921 RGD:2293607 |
NCBI chrNW_004624752:25,202,474...25,207,107
Ensembl chrNW_004624752:25,203,474...25,207,114
|
|
G |
Cldn1 |
claudin 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:33665778 |
|
NCBI chrNW_004624730:66,885,674...66,902,345
Ensembl chrNW_004624730:66,885,319...66,903,079
|
|
G |
Clptm1l |
CLPTM1 like |
|
ISO |
associated with esophagus squamous cell carcinoma; mRNA:increased expression:esophagus |
RGD |
PMID:25480402 |
RGD:150530497 |
NCBI chrNW_004624751:652,857...669,400
Ensembl chrNW_004624751:652,767...669,587
|
|
G |
Clu |
clusterin |
|
ISO |
associated with breast cancer;DNA:snp:promoter:g.27611345C>G (rs9331888) (human) |
RGD |
PMID:22037783 |
RGD:8963167 |
NCBI chrNW_004624758:22,431,331...22,444,185
Ensembl chrNW_004624758:22,426,918...22,444,357
|
|
G |
Comt |
catechol-O-methyltransferase |
|
ISO |
associated with breast cancer;DNA:missense mutation:cds:p.V108/158M (human) |
RGD |
PMID:10755383 |
RGD:8662330 |
NCBI chrNW_004624747:569,127...588,479
Ensembl chrNW_004624747:581,832...588,333
|
|
G |
Crp |
C-reactive protein |
susceptibility |
ISO |
associated with Breast Neoplasm; DNA:polymorphism: :1846C>T(rs1205)(human) |
RGD |
PMID:24633920 |
RGD:9580226 |
NCBI chrNW_004624794:1,531,555...1,533,804
Ensembl chrNW_004624794:1,531,571...1,533,804
|
|
G |
Csf1r |
colony stimulating factor 1 receptor |
|
ISO |
associated with Breast Neoplasms |
RGD |
PMID:14734466 |
RGD:2293711 |
NCBI chrNW_004624774:9,363,156...9,391,939
Ensembl chrNW_004624774:9,363,908...9,391,986
|
|
G |
Ctla4 |
cytotoxic T-lymphocyte associated protein 4 |
|
ISO |
associated with Prostatic Neoplasms |
RGD |
PMID:10611340 |
RGD:4891523 |
NCBI chrNW_004624765:12,449,205...12,454,324
Ensembl chrNW_004624765:12,449,205...12,454,324
|
|
G |
Ctnna1 |
catenin alpha 1 |
|
ISO |
associated with Breast Neoplasms |
RGD |
PMID:12047765 |
RGD:2289795 |
NCBI chrNW_004624743:31,512,481...31,700,340
|
|
G |
Ctnnb1 |
catenin beta 1 |
|
ISO |
associated with Breast Neoplasms;protein:decreased expression |
RGD |
PMID:17908479 |
RGD:2289813 |
NCBI chrNW_004624730:77,876,361...77,887,228
Ensembl chrNW_004624730:77,875,257...77,887,234
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
disease_progression |
ISO |
associated with stomach cancer;mRNA:increased expression:stomach (human) |
RGD |
PMID:21633638 |
RGD:152023624 |
NCBI chrNW_004624922:1,261,228...1,273,755
Ensembl chrNW_004624922:1,261,228...1,273,758
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
|
ISO |
associated with nasopharynx carcinoma; protein:increased expression:lymph node (human) |
RGD |
PMID:16000558 |
RGD:151893515 |
NCBI chrNW_004624732:35,473,740...35,477,482
Ensembl chrNW_004624732:35,472,760...35,477,528
|
|
G |
Ddr1 |
discoidin domain receptor tyrosine kinase 1 |
severity |
ISO |
mRNA:increased expression:kidney, lymph nodes (human) mRNA, protein:increased expression:mouth (human) |
RGD |
PMID:27020590 PMID:31253192 |
RGD:151347620 RGD:151347863 |
NCBI chrNW_004624754:24,881,439...24,905,633
Ensembl chrNW_004624754:24,880,496...24,896,995
|
|
G |
Ddr2 |
discoidin domain receptor tyrosine kinase 2 |
disease_progression |
ISO |
associated with oral squamous cell carcinoma |
RGD |
PMID:29945346 |
RGD:150429700 |
NCBI chrNW_004624826:1,225,217...1,255,889
Ensembl chrNW_004624826:1,173,621...1,249,692
|
|
G |
Dnmt3b |
DNA methyltransferase 3 beta |
|
ISO |
associated with Carcinoma, Pancreatic Ductal; |
RGD |
PMID:22919364 |
RGD:9589121 |
NCBI chrNW_004624842:6,450,972...6,505,929
Ensembl chrNW_004624842:6,450,852...6,475,785
|
|
G |
Ebag9 |
estrogen receptor binding site associated antigen 9 |
|
ISO |
associated with Prostatic Neoplasm;protein:increased expression:prostate gland, lymph node associated with Breast Neoplasms;protein:increased expression:breast |
RGD |
PMID:12054692 PMID:12845666 PMID:17187007 |
RGD:2289847 RGD:2289856 RGD:2298489 |
NCBI chrNW_004624763:8,621,666...8,649,109
Ensembl chrNW_004624763:8,621,638...8,650,016
|
|
G |
Egfr |
epidermal growth factor receptor |
treatment |
ISO |
associated with Squamous Cell Carcinoma of the Tongue |
RGD |
PMID:19380367 |
RGD:8551769 |
NCBI chrNW_004624740:584,133...713,205
Ensembl chrNW_004624740:589,606...713,271
|
|
G |
Ehmt2 |
euchromatic histone lysine methyltransferase 2 |
|
ISO |
associated with Melanoma; associated with Esophageal Squamous Cell Carcinoma; |
RGD |
PMID:24658378 PMID:24805087 |
RGD:9590069 RGD:9590071 |
NCBI chrNW_004624754:24,354,271...24,368,319
Ensembl chrNW_004624754:24,354,284...24,368,638
|
|
G |
Epha2 |
EPH receptor A2 |
|
ISO |
protein:increased expression:esophagus (human) |
RGD |
PMID:33833989 |
RGD:153344568 |
NCBI chrNW_004624764:2,265,114...2,296,032
Ensembl chrNW_004624764:2,264,945...2,296,197
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
disease_progression |
ISO |
associated with Carcinoma, Transitional Cell;protein:increased expression:urinary bladder associated with lung adenocarcinoma; protein:increased expression:lung (human) CTD Direct Evidence: marker/mechanism associated with Breast Neoplasms;DNA, protein:polymorphism, increased expression:serum:p.I655V |
RGD CTD |
PMID:18097576 PMID:18237248 PMID:21532492 PMID:21966491 |
RGD:153344600 RGD:2289925 RGD:2289926 |
NCBI chrNW_004624795:3,373,313...3,391,509
Ensembl chrNW_004624795:3,373,000...3,391,602
|
|
G |
Erbb3 |
erb-b2 receptor tyrosine kinase 3 |
|
ISO |
associated with head and neck squamous cell carcinoma associated with Prostatic Neoplasms;protein:increased expression, altered localization:lymph node, nucleus |
RGD |
PMID:17634423 PMID:20604875 |
RGD:126790467 RGD:2289944 |
NCBI chrNW_004624802:11,906,279...11,925,530
Ensembl chrNW_004624802:11,905,271...11,925,707
|
|
G |
Erbb4 |
erb-b2 receptor tyrosine kinase 4 |
severity disease_progression |
ISO |
associated with colorectal adenocarcinoma associated with lung non-small cell carcinoma associated with oral squamous cell carcinoma |
RGD |
PMID:16507107 PMID:21324275 PMID:27444519 |
RGD:126781762 RGD:126781766 RGD:126790471 |
NCBI chrNW_004624765:3,612,781...4,742,219
Ensembl chrNW_004624765:3,613,379...4,734,585
|
|
G |
Fas |
Fas cell surface death receptor |
susceptibility |
ISO |
associated with Cervix Neoplasms;DNA:polymorphism:promoter:-1377G>A |
RGD |
PMID:18068525 |
RGD:2298509 |
NCBI chrNW_004624791:15,290,022...15,315,848
Ensembl chrNW_004624791:15,289,348...15,315,848
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
|
ISO |
associated with Cervix Neoplasms;mRNA:increased expression:lymph node |
RGD |
PMID:17242701 |
RGD:2290286 |
NCBI chrNW_004624774:1,779,168...1,867,321
Ensembl chrNW_004624774:1,779,170...1,867,300
|
|
G |
Fgfr2 |
fibroblast growth factor receptor 2 |
|
ISO |
associated with breast cancer;DNA:snp:intron:c.109+7033T>A (rs1219648) (human) |
RGD |
PMID:20640597 |
RGD:7394846 |
NCBI chrNW_004624737:25,052,698...25,158,346
Ensembl chrNW_004624737:25,052,606...25,158,529
|
|
G |
Flt3 |
fms related receptor tyrosine kinase 3 |
disease_progression |
ISO |
associated with Prostatic Neoplasms |
RGD |
PMID:14566827 |
RGD:2302210 |
NCBI chrNW_004624776:10,407,083...10,516,350
Ensembl chrNW_004624776:10,435,850...10,517,066
|
|
G |
Foxa1 |
forkhead box A1 |
|
ISO |
associated with lung non-small cell carcinoma; mRNA:increased expression: : |
RGD |
PMID:29115441 |
RGD:151665751 |
NCBI chrNW_004624955:234,289...239,541
Ensembl chrNW_004624955:231,506...239,508
|
|
G |
Foxp1 |
forkhead box P1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:25485836 |
|
NCBI chrNW_004624773:5,543,529...6,076,522
Ensembl chrNW_004624773:5,543,536...5,883,131
|
|
G |
Gpx3 |
glutathione peroxidase 3 |
|
ISO |
associated with stomach carcinoma; DNA:hypermethylation:promoter |
RGD |
PMID:23071548 |
RGD:151665353 |
NCBI chrNW_004624733:40,957,895...40,963,469
Ensembl chrNW_004624733:40,957,999...40,962,993
|
|
G |
Grik2 |
glutamate ionotropic receptor kainate type subunit 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:30705370 |
|
NCBI chrNW_004624810:2,731,573...3,407,186
Ensembl chrNW_004624810:2,733,118...3,401,909
|
|
G |
Hmgb1 |
high mobility group box 1 |
|
ISO |
associated with Adenocarcinoma, Colon |
RGD |
PMID:20616616 |
RGD:10402080 |
NCBI chrNW_004624776:7,858,400...7,862,716
Ensembl chrNW_004624776:7,793,259...7,863,184
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
|
ISO |
associated with Breast Neoplasms |
RGD |
PMID:21590495 |
RGD:8547712 |
NCBI chrNW_004624828:2,432,584...2,451,997
Ensembl chrNW_004624828:2,432,550...2,453,071
|
|
G |
Ier2 |
immediate early response 2 |
|
ISO |
|
RGD |
PMID:22120713 |
RGD:153323322 |
NCBI chrNW_004624901:684,313...686,488
Ensembl chrNW_004624901:684,966...685,652
|
|
G |
Il13 |
interleukin 13 |
|
ISO |
associated with Melanoma, Cutaneous Malignant;mRNA:increased expression:lymph node |
RGD |
PMID:17545514 |
RGD:8549587 |
NCBI chrNW_004624733:39,427,189...39,430,019
Ensembl chrNW_004624733:39,428,095...39,429,843
|
|
G |
Il18 |
interleukin 18 |
|
ISO |
associated with Breast Neoplasms;protein:increased expression:serum |
RGD |
PMID:12902898 |
RGD:8655867 |
NCBI chrNW_004624784:7,294,286...7,312,959
Ensembl chrNW_004624784:7,294,183...7,304,687
|
|
G |
Ing4 |
inhibitor of growth family member 4 |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:27806345 |
|
NCBI chrNW_004624860:3,353,443...3,362,541
Ensembl chrNW_004624860:3,353,489...3,362,430
|
|
G |
Itgb1 |
integrin subunit beta 1 |
|
ISO |
associated with non-small cell lung carcinoma, |
RGD |
PMID:28537888 |
RGD:13792830 |
NCBI chrNW_004624805:8,748,848...8,800,259
Ensembl chrNW_004624805:8,765,949...8,802,149
|
|
G |
Kcnj12 |
potassium inwardly rectifying channel subfamily J member 12 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:34755307 |
|
NCBI chrNW_004624849:5,092,750...5,132,246
|
|
G |
Kdr |
kinase insert domain receptor |
treatment |
ISO |
associated with Squamous Cell Carcinoma of the Tongue |
RGD |
PMID:19380367 |
RGD:8551769 |
NCBI chrNW_004624761:14,330,224...14,380,680
Ensembl chrNW_004624761:14,330,489...14,379,051
|
|
G |
Kiss1 |
KiSS-1 metastasis suppressor |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:21383688 |
|
NCBI chrNW_004624807:6,800,144...6,805,555
Ensembl chrNW_004624807:6,803,265...6,805,433
|
|
G |
Klf7 |
KLF transcription factor 7 |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:37734194 |
|
NCBI chrNW_004624765:8,823,319...8,914,016
Ensembl chrNW_004624765:8,823,251...8,910,068
|
|
G |
Kmt2d |
lysine methyltransferase 2D |
|
ISO |
associated with stomach cancer |
RGD |
PMID:30177394 |
RGD:150521710 |
NCBI chrNW_004624816:3,129,127...3,169,143
Ensembl chrNW_004624816:3,133,659...3,166,346
|
|
G |
Lamc2 |
laminin subunit gamma 2 |
|
ISO |
associated with lung squamous cell carcinoma; |
RGD |
PMID:23124251 |
RGD:13793371 |
NCBI chrNW_004624814:10,475,629...10,536,694
Ensembl chrNW_004624814:10,476,323...10,536,724
|
|
G |
LOC101718508 |
cytochrome c, somatic |
|
ISO |
associated with non-small cell lung carcinoma; protein:decreased expression:serum |
RGD |
PMID:25578497 |
RGD:13792769 |
NCBI chrNW_004624739:5,411,192...5,413,995
Ensembl chrNW_004624739:5,411,273...5,413,995
|
|
G |
Lrrc59 |
leucine rich repeat containing 59 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:30705370 |
|
NCBI chrNW_004624795:6,317,677...6,328,554
Ensembl chrNW_004624795:6,316,472...6,329,166
|
|
G |
Macir |
macrophage immunometabolism regulator |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:30705370 |
|
NCBI chrNW_004624743:21,372,253...21,389,202
Ensembl chrNW_004624743:21,372,278...21,387,871
|
|
G |
Met |
MET proto-oncogene, receptor tyrosine kinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:29426936 |
|
NCBI chrNW_004624827:2,589,157...2,724,065
Ensembl chrNW_004624827:2,587,966...2,723,995
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
disease_progression |
ISO |
associated with Carcinoma, Ductal, Breast associated with Tongue Neoplasms |
RGD |
PMID:23107277 PMID:23280016 |
RGD:8547824 RGD:8655998 |
NCBI chrNW_004624757:1,450,680...1,479,160
Ensembl chrNW_004624757:1,448,698...1,479,255
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
|
ISO |
associated with breast cancer;DNA:deletion:promoter:-1170_-1172delA (human) |
RGD |
PMID:15161710 |
RGD:8662937 |
NCBI chrNW_004624878:39,282...47,386
Ensembl chrNW_004624878:39,358...47,075
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
disease_progression |
ISO |
associated with Tongue Neoplasms associated with Carcinoma, Non-Small-Cell Lung;protein:increased expression:serum associated with Endometrial Neoplasms;protein:increased expression:endometrium |
RGD |
PMID:12487935 PMID:20704821 PMID:23107277 |
RGD:2298523 RGD:5129215 RGD:8547824 |
NCBI chrNW_004624790:8,584,399...8,591,763
Ensembl chrNW_004624790:8,583,457...8,591,713
|
|
G |
Msh2 |
mutS homolog 2 |
|
ISO |
associated with laryngeal squamous cell carcinoma |
RGD |
PMID:24459922 |
RGD:126848797 |
NCBI chrNW_004624738:28,780,596...28,861,523
Ensembl chrNW_004624738:28,780,614...28,861,704
|
|
G |
Msln |
mesothelin |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22644300 |
|
NCBI chrNW_004624913:1,566,516...1,576,605
Ensembl chrNW_004624913:1,570,832...1,580,058
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:30705370 |
|
NCBI chrNW_004624818:1,570,155...1,698,264
Ensembl chrNW_004624818:1,570,276...1,698,259
|
|
G |
Muc1 |
mucin 1, cell surface associated |
|
ISO |
associated with Carcinoma, Renal Cell; associated with Esophageal Neoplasms associated with Common Bile Duct Neoplasms associated with Gallbladder Neoplasms;protein:altered localization:gallbladder |
RGD |
PMID:10390012 PMID:11295067 PMID:16222735 PMID:21339746 |
RGD:2324649 RGD:2324860 RGD:7245968 RGD:7349383 |
NCBI chrNW_004624885:2,339,281...2,343,351
|
|
G |
Muc5ac |
mucin 5AC, oligomeric mucus/gel-forming |
|
ISO |
associated with chloangiocarcinoma;protein:increased expression:bile duct |
RGD |
PMID:16842244 |
RGD:2325168 |
NCBI chrNW_004624766:21,439,023...21,461,108
|
|
G |
Ncam1 |
neural cell adhesion molecule 1 |
|
ISO |
|
RGD |
PMID:10086383 |
RGD:2326067 |
NCBI chrNW_004624784:8,339,582...8,635,025
Ensembl chrNW_004624784:8,339,916...8,636,012
|
|
G |
Nos3 |
nitric oxide synthase 3 |
susceptibility |
ISO |
associated with Breast Neoplasms;DNA:polymorphisms:promoter, exon:-786T>C,p.E298D (human) |
RGD |
PMID:17262178 |
RGD:2292070 |
NCBI chrNW_004624800:5,600,215...5,619,020
Ensembl chrNW_004624800:5,600,212...5,619,004
|
|
G |
Ogg1 |
8-oxoguanine DNA glycosylase |
|
ISO |
associated with breast cancer;DNA:missense mutation:cds:p.S326C (rs1052133) (human) |
RGD |
PMID:18977234 |
RGD:8657156 |
NCBI chrNW_004624731:4,383,000...4,388,486
Ensembl chrNW_004624731:4,383,434...4,388,196
|
|
G |
Pagr1 |
PAXIP1 associated glutamate rich protein 1 |
disease_progression |
ISO |
protein:decreased expression:esophagus (human) |
RGD |
PMID:33833989 |
RGD:153344568 |
NCBI chrNW_004624782:13,387,155...13,390,153
Ensembl chrNW_004624782:13,387,376...13,389,740
|
|
G |
Pdgfa |
platelet derived growth factor subunit A |
|
ISO |
associated with Breast Neoplasms;mRNA:increased expression:breast |
RGD |
PMID:8619189 |
RGD:2292155 |
NCBI chrNW_004624740:26,172,808...26,191,557
Ensembl chrNW_004624740:26,169,064...26,188,866
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
|
ISO |
associated with Breast Neoplasms;mRNA:increased expression:lymph node |
RGD |
PMID:17674348 |
RGD:2292173 |
NCBI chrNW_004624752:9,072,471...9,088,289
Ensembl chrNW_004624752:9,072,512...9,088,593
|
|
G |
Pdpk1 |
3-phosphoinositide dependent protein kinase 1 |
|
ISO |
associated with non-small cell lung carcinoma;mRNA:increased expression:blood serum |
RGD |
PMID:25064732 |
RGD:13503320 |
NCBI chrNW_004624824:279,893...383,220
Ensembl chrNW_004624824:293,374...383,156
|
|
G |
Pdpn |
podoplanin |
|
ISO |
associated with Cervix Neoplasms associated with Breast Neoplasms |
RGD |
PMID:16528371 PMID:18165897 |
RGD:2292231 RGD:2292237 |
NCBI chrNW_004624764:163,370...192,770
|
|
G |
Pebp1 |
phosphatidylethanolamine binding protein 1 |
|
ISO |
associated with Breast Neoplasms associated with Cervix Neoplasms |
RGD |
PMID:16243812 PMID:18191186 |
RGD:2302867 RGD:2302868 |
NCBI chrNW_004624747:15,340,020...15,346,960
Ensembl chrNW_004624747:15,339,844...15,346,970
|
|
G |
Pik3ca |
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
|
ISO |
associated with Colorectal Neoplasms |
RGD |
PMID:25550888 |
RGD:13432030 |
NCBI chrNW_004624730:56,895,065...56,970,563
Ensembl chrNW_004624730:56,938,215...56,966,137
|
|
G |
Pik3cb |
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta |
|
ISO |
associated with Colorectal Neoplasms |
RGD |
PMID:25550888 |
RGD:13432030 |
NCBI chrNW_004624730:15,226,786...15,399,097
Ensembl chrNW_004624730:15,226,379...15,355,857
|
|
G |
Pip5k1a |
phosphatidylinositol-4-phosphate 5-kinase type 1 alpha |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:34755307 |
|
NCBI chrNW_004624772:18,616,095...18,658,016
Ensembl chrNW_004624772:18,616,121...18,658,286
|
|
G |
Pou5f1 |
POU class 5 homeobox 1 |
|
ISO |
associated with Seminoma; associated with Carcinoma, Embryonal |
RGD |
PMID:15386301 |
RGD:2292442 |
NCBI chrNW_004624754:24,758,055...24,764,723
|
|
G |
Pparg |
peroxisome proliferator activated receptor gamma |
|
ISO |
associated with Cholangiocarcinoma;protein:increased expression:bile duct epithelium |
RGD |
PMID:20021832 |
RGD:2317459 |
NCBI chrNW_004624956:84,673...207,176
Ensembl chrNW_004624956:83,842...149,481
|
|
G |
Prex1 |
phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 1 |
|
ISO |
associated with Prostatic Neoplasms |
RGD |
PMID:19305425 |
RGD:2314605 |
NCBI chrNW_004624790:6,453,085...6,622,179
Ensembl chrNW_004624790:6,453,066...6,637,597
|
|
G |
Pten |
phosphatase and tensin homolog |
|
ISO |
associated with Prostatic Neoplasms;protein:decreased expression:prostate associated with Breast Neoplasms |
RGD |
PMID:17163422 PMID:17919877 |
RGD:2292499 RGD:2292507 |
NCBI chrNW_004624791:13,975,235...14,056,900
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
ISO |
associated with Biliary Tract Neoplasms associated with Breast Neoplasms associated with carcinoma, non-small-cell lung; DNA:SNP: :929G>C(human) |
RGD |
PMID:18159174 PMID:18353210 PMID:20016751 |
RGD:2300128 RGD:2317165 RGD:5135471 |
NCBI chrNW_004624814:6,897,818...6,904,890
Ensembl chrNW_004624814:6,897,857...6,903,728
|
|
G |
Ptk2 |
protein tyrosine kinase 2 |
|
ISO |
associated with lung squamous cell carcinoma; protein:increased tyrosine phosphorylation:lymph node |
RGD |
PMID:23906871 |
RGD:152176664 |
NCBI chrNW_004624735:15,356,911...15,713,219
Ensembl chrNW_004624735:15,461,178...15,714,071
|
|
G |
Ptpn13 |
protein tyrosine phosphatase non-receptor type 13 |
|
ISO |
associated with lung squamous cell carcinoma; protein:decreased expression:lymph node |
RGD |
PMID:23906871 |
RGD:152176664 |
NCBI chrNW_004624872:3,183,381...3,406,339
Ensembl chrNW_004624872:3,226,000...3,405,805
|
|
G |
Ramp2 |
receptor activity modifying protein 2 |
disease_progression |
ISO |
associated with colorectal cancer; protein:increased expression:lymph node (human) |
RGD |
PMID:23634287 |
RGD:151708733 |
NCBI chrNW_004624795:1,435,121...1,436,421
|
|
G |
Ramp3 |
receptor activity modifying protein 3 |
|
ISO |
associated with colorectal cancer; protein:increased expression:lymph node (human) |
RGD |
PMID:23634287 |
RGD:151708733 |
NCBI chrNW_004624740:7,240,841...7,249,313
Ensembl chrNW_004624740:7,241,296...7,249,410
|
|
G |
Rassf2 |
Ras association domain family member 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17013896 |
|
NCBI chrNW_004624741:5,851,260...5,894,972
Ensembl chrNW_004624741:5,857,607...5,894,969
|
|
G |
Rbm10 |
RNA binding motif protein 10 |
|
ISO |
associated with lung adenocarcinoma;DNA:missense mutation:exon:p.R241C (c.763C>T) (human) |
RGD |
PMID:30405763 |
RGD:151356993 |
NCBI chrNW_004624887:3,921,934...3,953,739
Ensembl chrNW_004624887:3,923,986...3,957,133
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
|
ISO |
associated with Prostatic Neoplasms;protein:altered localization:nucleus, prostate gland |
RGD |
PMID:17020979 |
RGD:2298757 |
NCBI chrNW_004624767:20,732,813...20,742,016
Ensembl chrNW_004624767:20,732,938...20,741,272
|
|
G |
Ret |
ret proto-oncogene |
|
ISO |
associated with Pancreatic Neoplasms |
RGD |
PMID:18652760 |
RGD:2324925 |
NCBI chrNW_004624922:382,462...413,227
Ensembl chrNW_004624922:382,399...413,281
|
|
G |
Rhoa |
ras homolog family member A |
|
ISO |
associated with Bladder Neoplasms;protein:increased expression:lymph node associated with colorectal cancer |
RGD |
PMID:12855641 PMID:17597401 |
RGD:13432052 RGD:2298872 |
NCBI chrNW_004624730:3,316,122...3,361,820
|
|
G |
Rictor |
RPTOR independent companion of MTOR complex 2 |
|
ISO |
associated with breast ductal carcinoma; protein:increased expression:breast tumor, lymph node (human) |
RGD |
PMID:20978191 |
RGD:152995469 |
NCBI chrNW_004624759:15,837,027...15,973,248
Ensembl chrNW_004624759:15,837,064...15,968,894
|
|
G |
Sfn |
stratifin |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19381893 |
|
NCBI chrNW_004624764:10,859,556...10,860,876
Ensembl chrNW_004624764:10,859,667...10,860,413
|
|
G |
Skp2 |
S-phase kinase associated protein 2 |
|
ISO |
associated with Endometrial Neoplasms;protein:increased expression:endometrium |
RGD |
PMID:16080017 |
RGD:2315043 |
NCBI chrNW_004624759:18,796,055...18,858,692
Ensembl chrNW_004624759:18,830,323...18,858,712
|
|
G |
Slc7a5 |
solute carrier family 7 member 5 |
severity |
ISO |
associated with stomach carcinoma associated with gastric adenocarcinoma;protein:increased expression: : |
RGD |
PMID:21501294 PMID:25908107 |
RGD:11052781 RGD:151361203 |
NCBI chrNW_004624746:1,325,368...1,349,616
|
|
G |
Smad4 |
SMAD family member 4 |
|
ISO |
associated with Breast Neoplasms |
RGD |
PMID:11809701 |
RGD:2300007 |
NCBI chrNW_004624778:14,570,025...14,629,950
Ensembl chrNW_004624778:14,570,348...14,630,325
|
|
G |
Smo |
smoothened, frizzled class receptor |
|
ISO |
associated with colorectal cancer |
RGD |
PMID:30784110 |
RGD:150520177 |
NCBI chrNW_004624783:7,012,385...7,039,302
Ensembl chrNW_004624783:7,011,899...7,039,921
|
|
G |
Sncg |
synuclein gamma |
|
ISO |
|
RGD |
PMID:15221989 |
RGD:6478801 |
NCBI chrNW_004624841:192,396...196,568
Ensembl chrNW_004624841:192,398...196,064
|
|
G |
Socs2 |
suppressor of cytokine signaling 2 |
|
ISO |
associated with Prostatic Neoplasms |
RGD |
PMID:16707422 |
RGD:2298925 |
NCBI chrNW_004624750:13,333,393...13,339,018
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
|
ISO |
associated with Breast Neoplasms |
RGD |
PMID:18097573 |
RGD:2298901 |
NCBI chrNW_004624801:7,841,230...7,843,912
Ensembl chrNW_004624801:7,840,889...7,843,860
|
|
G |
Sod2 |
superoxide dismutase 2 |
disease_progression |
ISO |
associated with tongue neoplasms; CTD Direct Evidence: marker/mechanism |
RGD CTD |
PMID:10853026 PMID:19381893 PMID:20618948 |
RGD:8547519 |
NCBI chrNW_004624855:3,260,800...3,271,864
Ensembl chrNW_004624855:3,260,809...3,271,367
|
|
G |
Sox2 |
SRY-box transcription factor 2 |
disease_progression |
ISO |
associated with Breast Neoplasms |
RGD |
PMID:24382260 |
RGD:8661670 |
NCBI chrNW_004624730:59,570,879...59,573,001
Ensembl chrNW_004624730:59,570,915...59,571,871
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
|
ISO |
associated with colon adenocarcinoma, |
RGD |
PMID:21282564 |
RGD:150520218 |
NCBI chrNW_004624842:2,212,561...2,260,514
Ensembl chrNW_004624842:2,211,020...2,230,132
|
|
G |
St14 |
ST14 transmembrane serine protease matriptase |
|
ISO |
associated with Endometrial Neoplasms |
RGD |
PMID:19443387 |
RGD:2315087 |
NCBI chrNW_004624812:4,584,043...4,620,410
Ensembl chrNW_004624812:4,583,946...4,620,547
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21549414 |
|
NCBI chrNW_004624795:1,648,235...1,680,788
Ensembl chrNW_004624795:1,648,080...1,681,200
|
|
G |
Stk11 |
serine/threonine kinase 11 |
|
ISO |
associated with Breast Neoplasms;protein:decreased expression |
RGD |
PMID:12114407 |
RGD:2291948 |
NCBI chrNW_004624828:7,444,339...7,466,926
Ensembl chrNW_004624828:7,445,069...7,467,298
|
|
G |
Tert |
telomerase reverse transcriptase |
disease_progression |
ISO |
associated with lung non-small cell carcinoma; |
RGD |
PMID:11679180 |
RGD:152977755 |
NCBI chrNW_004624751:624,569...647,198
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
|
ISO |
associated with Endometrial Neoplasms;protein:increased expression:endometrium |
RGD |
PMID:12487935 |
RGD:2298523 |
NCBI chrNW_004624978:120,723...125,006
Ensembl chrNW_004624978:121,803...124,912
|
|
G |
Timp3 |
TIMP metallopeptidase inhibitor 3 |
|
ISO |
associated with Breast Neoplasms;mRNA:increased expression:breast |
RGD |
PMID:12828172 |
RGD:2290437 |
NCBI chrNW_004624750:1,776,197...1,817,279
Ensembl chrNW_004624750:1,775,744...1,817,385
|
|
G |
Timp4 |
TIMP metallopeptidase inhibitor 4 |
|
ISO |
associated with Breast Neoplasms;mRNA:increased expression:breast |
RGD |
PMID:12828172 |
RGD:2290437 |
NCBI chrNW_004624956:331,275...341,561
Ensembl chrNW_004624956:330,327...337,299
|
|
G |
Tlr4 |
toll like receptor 4 |
|
ISO |
associated with Carcinoma, Ductal, Breast; |
RGD |
PMID:23338716 |
RGD:7794684 |
NCBI chrNW_004624760:17,596,516...17,608,955
Ensembl chrNW_004624760:17,598,630...17,609,120
|
|
G |
Tp53 |
tumor protein p53 |
|
ISO |
associated with Breast Neoplasms;DNA:missense mutation, duplication:cds, intron:p.R72P associated with Penile Neoplasms associated with Carcinoma, Squamous Cell; |
RGD |
PMID:18059331 PMID:18230179 PMID:18268397 |
RGD:2290533 RGD:2290534 RGD:8547790 |
NCBI chrNW_004624786:10,266,316...10,282,664
Ensembl chrNW_004624786:10,263,518...10,271,218
|
|
G |
Tp53bp1 |
tumor protein p53 binding protein 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:30705370 |
|
NCBI chrNW_004624804:10,517,531...10,612,238
Ensembl chrNW_004624804:10,517,696...10,591,688
|
|
G |
Tsc2 |
TSC complex subunit 2 |
|
ISO |
associated with Breast Neoplasms |
RGD |
PMID:15951164 |
RGD:11568707 |
NCBI chrNW_004624913:166,931...203,008
Ensembl chrNW_004624913:166,931...202,953
|
|
G |
Tshr |
thyroid stimulating hormone receptor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:9062474 |
|
NCBI chrNW_004624734:20,880,438...21,050,756
Ensembl chrNW_004624734:20,882,154...21,050,626
|
|
G |
Ttr |
transthyretin |
|
ISO |
associated with colorectal cancer;protein:decreased expresion:blood serum (human) |
RGD |
PMID:21074777 |
RGD:151665155 |
NCBI chrNW_004624770:1,255,401...1,262,019
Ensembl chrNW_004624770:1,251,716...1,262,213
|
|
G |
Tymp |
thymidine phosphorylase |
|
ISO |
associated with Breast Neoplasms associated with Cholangiocarcinoma |
RGD |
PMID:10685502 PMID:11927969 |
RGD:2293725 RGD:2325027 |
NCBI chrNW_004624752:251,670...256,243
Ensembl chrNW_004624752:252,937...256,244
|
|
G |
Vegfa |
vascular endothelial growth factor A |
|
ISO |
associated with Breast neoplasms; associated with Cervix Neoplasms |
RGD |
PMID:17597103 PMID:19783962 |
RGD:2315454 RGD:7421574 |
NCBI chrNW_004624754:15,929,414...15,943,637
|
|
G |
Vegfc |
vascular endothelial growth factor C |
exacerbates disease_progression |
ISO |
associated with Lymphatic Metastasis; associated with pancreatic adenocarcinoma;protein:increased expression:pancreas (human) associated with Breast Neoplasms associated with Prostatic Neoplasms associated with thyroid diseases;mRNA:increased expression:thyroid gland: associated with Carcinoma, Transitional Cell;protein:increased expression:urinary bladder associated with Cervix Neoplasms |
RGD |
PMID:12203051 PMID:15289890 PMID:17034609 PMID:18061373 PMID:19589137 PMID:19608016 PMID:19923084 More...
|
RGD:155630642 RGD:2315469 RGD:2315474 RGD:2315475 RGD:2315484 RGD:7483611 RGD:7488946 |
NCBI chrNW_004624769:7,689,812...7,817,366
Ensembl chrNW_004624769:7,689,407...7,817,450
|
|
G |
Vegfd |
vascular endothelial growth factor D |
|
ISO |
associated with Cervix Neoplasms associated with Breast Neoplasms |
RGD |
PMID:17951197 PMID:19589137 |
RGD:2315475 RGD:2315480 |
NCBI chrNW_004624829:148,371...181,742
Ensembl chrNW_004624829:148,317...181,098
|
|
G |
Wrap53 |
WD repeat containing antisense to TP53 |
|
ISO |
associated with esophagus squamous cell carcinoma; associated with lung non-small cell carcinoma; |
RGD |
PMID:24626331 PMID:31281482 |
RGD:21081513 RGD:21081532 |
NCBI chrNW_004624786:10,283,721...10,296,568
Ensembl chrNW_004624786:10,283,984...10,296,729
|
|
|
G |
Aco1 |
aconitase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20390345 |
|
NCBI chrNW_004624736:37,063,540...37,127,772
Ensembl chrNW_004624736:37,063,246...37,126,702
|
|
G |
Actb |
actin beta |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15654357 |
|
NCBI chrNW_004624740:28,087,051...28,090,359
Ensembl chrNW_004624740:28,087,736...28,090,512
|
|
G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:23289900 |
|
NCBI chrNW_004624745:14,802,703...14,811,568
Ensembl chrNW_004624745:14,802,371...14,811,203
|
|
G |
Ahnak |
AHNAK nucleoprotein |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20388789 |
|
NCBI chrNW_004624926:1,071,969...1,101,587
|
|
G |
Ahr |
aryl hydrocarbon receptor |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:25826687 PMID:27752740 |
|
NCBI chrNW_004624739:12,939,183...12,987,574
Ensembl chrNW_004624739:12,942,165...12,987,973
|
|
G |
Alkbh8 |
alkB homolog 8, tRNA methyltransferase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27811057 |
|
NCBI chrNW_004624784:2,255,492...2,373,824
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20061081 |
|
NCBI chrNW_004624966:168,244...220,430
Ensembl chrNW_004624966:168,250...220,522
|
|
G |
Ambp |
alpha-1-microglobulin/bikunin precursor |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:14644129 |
|
NCBI chrNW_004624760:21,047,576...21,064,698
Ensembl chrNW_004624760:21,047,303...21,068,076
|
|
G |
Amotl1 |
angiomotin like 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:34480788 |
|
NCBI chrNW_004624735:39,393,567...39,544,266
Ensembl chrNW_004624735:39,435,338...39,539,826
|
|
G |
Angpt1 |
angiopoietin 1 |
|
ISO |
associated with Mammary Neoplasms, Animal;mRNA:increased expression:mammary gland |
RGD |
PMID:15459484 |
RGD:1626167 |
NCBI chrNW_004624763:22,645,807...22,818,592
Ensembl chrNW_004624763:22,646,231...22,718,294
|
|
G |
Angptl4 |
angiopoietin like 4 |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:17130448 |
|
NCBI chrNW_004624828:1,152,788...1,158,864
Ensembl chrNW_004624828:1,152,891...1,158,420
|
|
G |
Anxa1 |
annexin A1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15654357 |
|
NCBI chrNW_004624811:765,338...782,203
Ensembl chrNW_004624811:764,940...782,198
|
|
G |
Anxa2 |
annexin A2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15654357 |
|
NCBI chrNW_004624781:11,781,893...11,820,440
Ensembl chrNW_004624781:11,781,886...11,821,816
|
|
G |
Arf1 |
ARF GTPase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27517156 |
|
NCBI chrNW_004624937:857,795...871,089
|
|
G |
Axl |
AXL receptor tyrosine kinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26206560 |
|
NCBI chrNW_004624907:76,236...106,765
Ensembl chrNW_004624907:77,806...106,228
|
|
G |
Bcar1 |
BCAR1 scaffold protein, Cas family member |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21291860 |
|
NCBI chrNW_004624746:11,660,859...11,695,991
Ensembl chrNW_004624746:11,660,426...11,695,988
|
|
G |
Brms1 |
BRMS1 transcriptional repressor and anoikis regulator |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:27501413 |
|
NCBI chrNW_004624767:20,036,190...20,043,871
Ensembl chrNW_004624767:20,036,256...20,043,876
|
|
G |
Bsg |
basigin (Ok blood group) |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21165561 |
|
NCBI chrNW_004624828:7,913,297...7,920,891
Ensembl chrNW_004624828:7,913,099...7,920,804
|
|
G |
Calr |
calreticulin |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15048980 |
|
NCBI chrNW_004624901:511,295...515,208
Ensembl chrNW_004624901:511,052...516,757
|
|
G |
Calu |
calumenin |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15048980 |
|
NCBI chrNW_004624783:7,417,505...7,448,711
|
|
G |
Cat |
catalase |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:21749277 PMID:22580338 |
|
NCBI chrNW_004624767:12,680,940...12,715,468
Ensembl chrNW_004624767:12,680,953...12,715,739
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:18985009 |
|
NCBI chrNW_004624875:3,334,136...3,342,085
Ensembl chrNW_004624875:3,334,078...3,341,614
|
|
G |
Cd82 |
CD82 molecule |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:20075392 |
|
NCBI chrNW_004624767:3,556,128...3,589,956
|
|
G |
Cdh1 |
cadherin 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism|therapeutic |
CTD |
PMID:19839049 PMID:22580338 |
|
NCBI chrNW_004624746:17,480,472...17,557,722
Ensembl chrNW_004624746:17,483,469...17,557,581
|
|
G |
Cdh2 |
cadherin 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27811057 |
|
NCBI chrNW_004624770:4,333,643...4,540,817
Ensembl chrNW_004624770:4,334,202...4,545,470
|
|
G |
Cfl1 |
cofilin 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15048980 |
|
NCBI chrNW_004624767:20,574,884...20,578,413
Ensembl chrNW_004624767:20,574,966...20,579,796
|
|
G |
Chi3l1 |
chitinase 3 like 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21029458 |
|
NCBI chrNW_004624807:7,655,777...7,664,484
Ensembl chrNW_004624807:7,655,620...7,662,362
|
|
G |
Chrna7 |
cholinergic receptor nicotinic alpha 7 subunit |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:18844224 |
|
NCBI chrNW_004624768:908,907...1,024,953
Ensembl chrNW_004624768:909,099...1,024,902
|
|
G |
Cse1l |
chromosome segregation 1 like |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:34022224 |
|
NCBI chrNW_004624790:6,238,702...6,280,456
Ensembl chrNW_004624790:6,239,496...6,280,394
|
|
G |
Cstb |
cystatin B |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19747051 PMID:22287159 |
|
NCBI chrNW_004624745:30,152,988...30,155,704
Ensembl chrNW_004624745:30,153,023...30,155,712
|
|
G |
Ctbp2 |
C-terminal binding protein 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28414304 |
|
NCBI chrNW_004624737:22,135,046...22,166,580
Ensembl chrNW_004624737:22,003,871...22,165,257
|
|
G |
Ctnnb1 |
catenin beta 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:23707762 PMID:26990689 |
|
NCBI chrNW_004624730:77,876,361...77,887,228
Ensembl chrNW_004624730:77,875,257...77,887,234
|
|
G |
Ctsb |
cathepsin B |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19700239 PMID:19747051 |
|
NCBI chrNW_004624758:25,366,120...25,384,554
Ensembl chrNW_004624758:25,366,840...25,373,954
|
|
G |
Ctsd |
cathepsin D |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15048980 |
|
NCBI chrNW_004624767:14,661,058...14,671,116
Ensembl chrNW_004624767:14,660,936...14,671,671
|
|
G |
Ctss |
cathepsin S |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19700239 |
|
NCBI chrNW_004624772:18,421,905...18,446,857
Ensembl chrNW_004624772:18,419,736...18,438,786
|
|
G |
Ctu1 |
cytosolic thiouridylase subunit 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27811057 |
|
NCBI chrNW_004624832:3,433,809...3,438,847
|
|
G |
Ctu2 |
cytosolic thiouridylase subunit 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27811057 |
|
NCBI chrNW_004624746:871,707...878,047
Ensembl chrNW_004624746:871,668...877,719
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19700239 PMID:25231984 PMID:25753200 |
|
NCBI chrNW_004624922:1,261,228...1,273,755
Ensembl chrNW_004624922:1,261,228...1,273,758
|
|
G |
Cxcl8 |
C-X-C motif chemokine ligand 8 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:32512068 |
|
NCBI chrNW_004624730:1,744,097...1,747,206
Ensembl chrNW_004624730:1,743,916...1,747,293
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:25753200 |
|
NCBI chrNW_004624732:35,473,740...35,477,482
Ensembl chrNW_004624732:35,472,760...35,477,528
|
|
G |
Dek |
DEK proto-oncogene |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21291860 PMID:27811057 |
|
NCBI chrNW_004624756:8,421,492...8,447,452
Ensembl chrNW_004624756:8,421,782...8,447,452
|
|
G |
Dlx4 |
distal-less homeobox 4 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 |
|
NCBI chrNW_004624795:5,995,364...6,000,472
Ensembl chrNW_004624795:5,995,085...6,000,566
|
|
G |
Dmd |
dystrophin |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:24793134 |
|
NCBI chrNW_004624762:22,306,962...24,846,427
Ensembl chrNW_004624762:22,746,729...24,847,938
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28544374 |
|
NCBI chrNW_004624828:2,316,042...2,358,866
Ensembl chrNW_004624828:2,315,251...2,358,711
|
|
G |
Ednrb |
endothelin receptor type B |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 |
|
NCBI chrNW_004624751:22,459,613...22,491,409
Ensembl chrNW_004624751:22,459,584...22,491,606
|
|
G |
Eef2 |
eukaryotic translation elongation factor 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21554491 |
|
NCBI chrNW_004624828:5,601,906...5,609,978
Ensembl chrNW_004624828:5,601,444...5,611,405
|
|
G |
Egfr |
epidermal growth factor receptor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:18844224 PMID:23867902 |
|
NCBI chrNW_004624740:584,133...713,205
Ensembl chrNW_004624740:589,606...713,271
|
|
G |
Elp1 |
elongator acetyltransferase complex subunit 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27811057 |
|
NCBI chrNW_004624758:2,575,516...2,646,313
Ensembl chrNW_004624758:2,575,671...2,646,313
|
|
G |
Elp3 |
elongator acetyltransferase complex subunit 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27811057 |
|
NCBI chrNW_004624758:22,838,077...22,904,627
Ensembl chrNW_004624758:22,837,374...22,903,714
|
|
G |
En1 |
engrailed homeobox 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 |
|
NCBI chrNW_004624732:26,333,642...26,338,450
Ensembl chrNW_004624732:26,333,653...26,337,904
|
|
G |
Eno1 |
enolase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15654357 |
|
NCBI chrNW_004624818:3,223,384...3,235,128
Ensembl chrNW_004624818:3,223,308...3,238,419
|
|
G |
Epas1 |
endothelial PAS domain protein 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26735578 PMID:30090327 |
|
NCBI chrNW_004624738:27,747,770...27,831,213
Ensembl chrNW_004624738:27,747,696...27,834,054
|
|
G |
Epor |
erythropoietin receptor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:16699298 |
|
NCBI chrNW_004624828:3,181,772...3,187,242
Ensembl chrNW_004624828:3,181,957...3,187,231
|
|
G |
Eps8 |
EGFR pathway substrate 8, signaling adaptor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19799886 |
|
NCBI chrNW_004624752:22,250,988...22,424,957
Ensembl chrNW_004624752:22,295,413...22,426,717
|
|
G |
Esr1 |
estrogen receptor 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism|therapeutic |
CTD |
PMID:26990689 PMID:27366082 PMID:35044086 |
|
NCBI chrNW_004624785:6,164,507...6,601,302
Ensembl chrNW_004624785:6,164,379...6,601,326
|
|
G |
Fgfr4 |
fibroblast growth factor receptor 4 |
|
ISO |
ClinVar Annotator: match by term: Cancer progression and tumor cell motility |
ClinVar |
PMID:11830541 PMID:25741868 PMID:26675719 PMID:33116287 |
|
NCBI chrNW_004624733:12,964,893...12,979,198
Ensembl chrNW_004624733:12,964,746...12,976,732
|
|
G |
Fn1 |
fibronectin 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:24014025 |
|
NCBI chrNW_004624765:707,872...775,056
Ensembl chrNW_004624765:707,755...775,056
|
|
G |
Foxp1 |
forkhead box P1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:25485836 |
|
NCBI chrNW_004624773:5,543,529...6,076,522
Ensembl chrNW_004624773:5,543,536...5,883,131
|
|
G |
Fth1 |
ferritin heavy chain 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20390345 |
|
NCBI chrNW_004624926:469,870...471,142
|
|
G |
Ftl |
ferritin light chain |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20390345 |
|
NCBI chrNW_004624832:5,046,207...5,047,828
Ensembl chrNW_004624832:5,046,208...5,047,828
|
|
G |
Gab2 |
GRB2 associated binding protein 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21996746 |
|
NCBI chrNW_004624863:1,216,664...1,410,934
Ensembl chrNW_004624863:1,219,866...1,281,847
|
|
G |
Hdac3 |
histone deacetylase 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:34973135 |
|
NCBI chrNW_004624774:845,970...864,080
Ensembl chrNW_004624774:845,358...863,809
|
|
G |
Hgf |
hepatocyte growth factor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:9932610 PMID:15654357 |
|
NCBI chrNW_004624739:30,233,589...30,307,508
Ensembl chrNW_004624739:30,236,146...30,307,356
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:12811834 PMID:29501572 |
|
NCBI chrNW_004624734:39,414,458...39,471,705
Ensembl chrNW_004624734:39,411,824...39,471,705
|
|
G |
Hmga2 |
high mobility group AT-hook 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28830677 |
|
NCBI chrNW_004624802:2,337,344...2,468,757
Ensembl chrNW_004624802:2,337,464...2,467,990
|
|
G |
Hmgcs2 |
3-hydroxy-3-methylglutaryl-CoA synthase 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27816970 |
|
NCBI chrNW_004624772:15,432,612...15,464,343
Ensembl chrNW_004624772:15,432,198...15,467,797
|
|
G |
Hmox1 |
heme oxygenase 1 |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:24211270 |
|
NCBI chrNW_004624750:341,699...346,005
Ensembl chrNW_004624750:342,146...345,887
|
|
G |
Hoxb13 |
homeobox B13 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 |
|
NCBI chrNW_004624795:5,198,805...5,201,079
Ensembl chrNW_004624795:5,198,751...5,200,961
|
|
G |
Hoxb3 |
homeobox B3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:34652879 |
|
NCBI chrNW_004624795:5,050,272...5,072,614
Ensembl chrNW_004624795:5,048,920...5,068,708
|
|
G |
Hpse |
heparanase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22240343 |
|
NCBI chrNW_004624900:296,626...335,624
Ensembl chrNW_004624900:296,676...335,570
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:23877152 |
|
NCBI chrNW_004624766:21,907,423...21,913,414
Ensembl chrNW_004624766:21,911,241...21,913,653
|
|
G |
Id4 |
inhibitor of DNA binding 4, HLH protein |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:14633621 |
|
NCBI chrNW_004624756:6,816,364...6,819,144
Ensembl chrNW_004624756:6,814,842...6,819,578
|
|
G |
Igf1 |
insulin like growth factor 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:18398872 |
|
NCBI chrNW_004624750:5,881,065...5,954,799
Ensembl chrNW_004624750:5,881,091...5,952,300
|
|
G |
Il1b |
interleukin 1 beta |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27567548 |
|
NCBI chrNW_004624749:12,852,128...12,858,478
Ensembl chrNW_004624749:12,852,021...12,858,760
|
|
G |
Il1rn |
interleukin 1 receptor antagonist |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:27567548 |
|
NCBI chrNW_004624749:13,210,365...13,224,471
Ensembl chrNW_004624749:13,210,476...13,225,890
|
|
G |
Il6 |
interleukin 6 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26101800 PMID:26284488 |
|
NCBI chrNW_004624739:7,957,709...7,963,414
Ensembl chrNW_004624739:7,957,674...7,962,318
|
|
G |
Ins |
insulin |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:24587105 |
|
NCBI chrNW_004624767:14,999,088...15,000,035
Ensembl chrNW_004624767:14,999,088...15,000,035
|
|
G |
Ireb2 |
iron responsive element binding protein 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20390345 |
|
NCBI chrNW_004624894:2,446,014...2,498,650
Ensembl chrNW_004624894:2,445,704...2,499,009
|
|
G |
Itga5 |
integrin subunit alpha 5 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21224397 |
|
NCBI chrNW_004624904:2,418,140...2,439,945
Ensembl chrNW_004624904:2,417,269...2,440,087
|
|
G |
Itgb1 |
integrin subunit beta 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21224397 |
|
NCBI chrNW_004624805:8,748,848...8,800,259
Ensembl chrNW_004624805:8,765,949...8,802,149
|
|
G |
Itpk1 |
inositol-tetrakisphosphate 1-kinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 |
|
NCBI chrNW_004624734:9,420,232...9,568,655
Ensembl chrNW_004624734:9,417,939...9,568,702
|
|
G |
Kcnd2 |
potassium voltage-gated channel subfamily D member 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:34418280 |
|
NCBI chrNW_004624783:15,349,416...15,892,011
Ensembl chrNW_004624783:15,351,870...15,891,057
|
|
G |
Kdm1a |
lysine demethylase 1A |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22493729 |
|
NCBI chrNW_004624764:7,664,550...7,742,494
|
|
G |
Krt7 |
keratin 7 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19921857 |
|
NCBI chrNW_004624816:103,285...168,486
Ensembl chrNW_004624816:105,758...134,567
|
|
G |
Ldhb |
lactate dehydrogenase B |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15048980 |
|
NCBI chrNW_004624752:17,046,640...17,065,910
Ensembl chrNW_004624752:17,049,296...17,069,553
|
|
G |
Lef1 |
lymphoid enhancer binding factor 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27811057 |
|
NCBI chrNW_004624830:1,320,034...1,422,774
Ensembl chrNW_004624830:1,321,387...1,424,389
|
|
G |
Lin28a |
lin-28 homolog A |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26910839 |
|
NCBI chrNW_004624764:10,426,168...10,441,541
|
|
G |
LOC101719398 |
serotransferrin |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20390345 |
|
NCBI chrNW_004624730:10,078,165...10,109,349
|
|
G |
LOC101722366 |
cytochrome P450 2E1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 |
|
NCBI chrNW_004624737:12,335,733...12,345,278
Ensembl chrNW_004624737:12,335,681...12,345,514
|
|
G |
Loxl2 |
lysyl oxidase like 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:24014025 |
|
NCBI chrNW_004624758:18,567,367...18,644,528
Ensembl chrNW_004624758:18,568,607...18,621,785
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22580338 |
|
NCBI chrNW_004624747:1,296,062...1,389,674
Ensembl chrNW_004624747:1,296,221...1,389,757
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22580338 |
|
NCBI chrNW_004624782:13,150,824...13,158,327
Ensembl chrNW_004624782:13,152,039...13,159,113
|
|
G |
Met |
MET proto-oncogene, receptor tyrosine kinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15654357 |
|
NCBI chrNW_004624827:2,589,157...2,724,065
Ensembl chrNW_004624827:2,587,966...2,723,995
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22580338 |
|
NCBI chrNW_004624878:71,642...79,660
Ensembl chrNW_004624878:71,642...79,602
|
|
G |
Mmp14 |
matrix metallopeptidase 14 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:24014025 |
|
NCBI chrNW_004624820:9,667,371...9,677,488
Ensembl chrNW_004624820:9,667,262...9,677,774
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:18398872 PMID:19770485 PMID:22321834 PMID:23707804 PMID:34278709 |
|
NCBI chrNW_004624757:1,450,680...1,479,160
Ensembl chrNW_004624757:1,448,698...1,479,255
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20188714 PMID:26284488 |
|
NCBI chrNW_004624878:39,282...47,386
Ensembl chrNW_004624878:39,358...47,075
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19617202 PMID:19700239 PMID:20188714 PMID:21187089 PMID:22503731 PMID:23867902 PMID:24333868 More...
|
|
NCBI chrNW_004624790:8,584,399...8,591,763
Ensembl chrNW_004624790:8,583,457...8,591,713
|
|
G |
Mtdh |
metadherin |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:29315995 |
|
NCBI chrNW_004624763:4,905,261...4,967,014
Ensembl chrNW_004624763:4,905,044...4,967,014
|
|
G |
Myd88 |
MYD88 innate immune signal transduction adaptor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21473897 |
|
NCBI chrNW_004624731:2,677,259...2,681,408
Ensembl chrNW_004624731:2,677,290...2,681,489
|
|
G |
Myh9 |
myosin heavy chain 9 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28650484 |
|
NCBI chrNW_004624752:11,327,881...11,414,037
Ensembl chrNW_004624752:11,327,877...11,413,669
|
|
G |
Mylk |
myosin light chain kinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:10232591 PMID:12970723 |
|
NCBI chrNW_004624912:1,952,053...2,213,196
Ensembl chrNW_004624912:1,953,838...2,172,561
|
|
G |
Ncam1 |
neural cell adhesion molecule 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19700239 |
|
NCBI chrNW_004624784:8,339,582...8,635,025
Ensembl chrNW_004624784:8,339,916...8,636,012
|
|
G |
Nek2 |
NIMA related kinase 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28509438 |
|
NCBI chrNW_004624771:17,334,782...17,351,609
Ensembl chrNW_004624771:17,334,681...17,352,259
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:32682831 |
|
NCBI chrNW_004624787:14,355,330...14,381,353
Ensembl chrNW_004624787:14,355,791...14,381,251
|
|
G |
Notch2 |
notch receptor 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:30670679 |
|
NCBI chrNW_004624772:15,572,350...15,726,312
Ensembl chrNW_004624772:15,571,998...15,726,426
|
|
G |
Nrg1 |
neuregulin 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19617202 |
|
NCBI chrNW_004624780:11,297,306...11,525,236
Ensembl chrNW_004624780:11,301,182...12,424,066
|
|
G |
Nuak1 |
NUAK family kinase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 PMID:26873845 |
|
NCBI chrNW_004624750:3,141,442...3,197,821
Ensembl chrNW_004624750:3,141,441...3,197,514
|
|
G |
Pak1 |
p21 (RAC1) activated kinase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:35066776 |
|
NCBI chrNW_004624863:442,465...609,159
Ensembl chrNW_004624863:439,541...525,918
|
|
G |
Pax6 |
paired box 6 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 |
|
NCBI chrNW_004624766:20,536,581...20,554,589
Ensembl chrNW_004624766:20,536,233...20,554,759
|
|
G |
Pdcd4 |
programmed cell death 4 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:23272133 |
|
NCBI chrNW_004624737:35,414,078...35,451,023
|
|
G |
Pip5k1a |
phosphatidylinositol-4-phosphate 5-kinase type 1 alpha |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:34755307 |
|
NCBI chrNW_004624772:18,616,095...18,658,016
Ensembl chrNW_004624772:18,616,121...18,658,286
|
|
G |
Pkm |
pyruvate kinase M1/2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15048980 PMID:15654357 |
|
NCBI chrNW_004624781:1,796,909...1,823,787
Ensembl chrNW_004624781:1,796,801...1,824,144
|
|
G |
Plau |
plasminogen activator, urokinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:14644129 PMID:26284488 |
|
NCBI chrNW_004624754:7,405,637...7,415,870
Ensembl chrNW_004624754:7,408,983...7,416,559
|
|
G |
Plaur |
plasminogen activator, urokinase receptor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
RGD CTD |
PMID:12198772 PMID:22261521 |
RGD:729319 |
NCBI chrNW_004624907:1,174,648...1,188,919
Ensembl chrNW_004624907:1,174,448...1,189,377
|
|
G |
Ppp1r12b |
protein phosphatase 1 regulatory subunit 12B |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28650484 |
|
NCBI chrNW_004624807:8,203,118...8,414,121
Ensembl chrNW_004624807:8,209,547...8,414,511
|
|
G |
Prdx2 |
peroxiredoxin 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:23911960 |
|
NCBI chrNW_004624901:407,240...410,902
Ensembl chrNW_004624901:406,257...410,866
|
|
G |
Pten |
phosphatase and tensin homolog |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:21994956 |
|
NCBI chrNW_004624791:13,975,235...14,056,900
|
|
G |
Ptk2 |
protein tyrosine kinase 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism|therapeutic |
CTD |
PMID:12811834 PMID:25199511 |
|
NCBI chrNW_004624735:15,356,911...15,713,219
Ensembl chrNW_004624735:15,461,178...15,714,071
|
|
G |
Rab27a |
RAB27A, member RAS oncogene family |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:34291859 |
|
NCBI chrNW_004624731:6,315,064...6,355,431
Ensembl chrNW_004624731:6,319,092...6,355,534
|
|
G |
Rab27b |
RAB27B, member RAS oncogene family |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:34291859 |
|
NCBI chrNW_004624792:166,846...368,906
Ensembl chrNW_004624792:307,608...363,568
|
|
G |
Rasal2 |
RAS protein activator like 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:34826200 |
|
NCBI chrNW_004624771:3,791,337...4,125,982
Ensembl chrNW_004624771:3,797,187...4,126,379
|
|
G |
Rbm38 |
RNA binding motif protein 38 |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:34453780 |
|
NCBI chrNW_004624741:23,854,069...23,868,016
Ensembl chrNW_004624741:23,854,023...23,868,345
|
|
G |
Reck |
reversion inducing cysteine rich protein with kazal motifs |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:20127710 |
|
NCBI chrNW_004624868:4,604,157...4,713,838
Ensembl chrNW_004624868:4,603,955...4,713,652
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19896475 PMID:29501572 |
|
NCBI chrNW_004624767:20,732,813...20,742,016
Ensembl chrNW_004624767:20,732,938...20,741,272
|
|
G |
Rhoa |
ras homolog family member A |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19896475 |
|
NCBI chrNW_004624730:3,316,122...3,361,820
|
|
G |
Rnf207 |
ring finger protein 207 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 |
|
NCBI chrNW_004624818:5,176,316...5,183,610
Ensembl chrNW_004624818:5,178,299...5,183,610
|
|
G |
Rpl3l |
ribosomal protein L3 like |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 |
|
NCBI chrNW_004624913:301,921...310,655
Ensembl chrNW_004624913:301,938...310,469
|
|
G |
Rps6ka3 |
ribosomal protein S6 kinase A3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21488662 |
|
NCBI chrNW_004624829:4,978,181...5,087,493
Ensembl chrNW_004624829:4,983,282...5,087,485
|
|
G |
Rpsa |
ribosomal protein SA |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15048980 |
|
NCBI chrNW_004624730:78,808,270...78,813,782
|
|
G |
S100a11 |
S100 calcium binding protein A11 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20388789 |
|
NCBI chrNW_004624772:19,563,871...19,568,413
Ensembl chrNW_004624772:19,563,889...19,568,766
|
|
G |
S100a4 |
S100 calcium binding protein A4 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15048980 |
|
NCBI chrNW_004624885:3,589,323...3,591,463
Ensembl chrNW_004624885:3,586,909...3,592,914
|
|
G |
S1pr2 |
sphingosine-1-phosphate receptor 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26518876 |
|
NCBI chrNW_004624828:2,371,750...2,419,330
Ensembl chrNW_004624828:2,390,742...2,394,106
|
|
G |
Septin9 |
septin 9 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20388789 |
|
NCBI chrNW_004624801:6,988,914...7,156,469
Ensembl chrNW_004624801:6,988,904...7,159,072
|
|
G |
Set |
SET nuclear proto-oncogene |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:24555657 |
|
NCBI chrNW_004624760:6,293,452...6,304,237
|
|
G |
Slc39a10 |
solute carrier family 39 member 10 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17359283 |
|
NCBI chrNW_004624854:1,163,025...1,280,717
|
|
G |
Slc6a12 |
solute carrier family 6 member 12 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 |
|
NCBI chrNW_004624735:8,441,046...8,469,611
Ensembl chrNW_004624735:8,445,405...8,468,083
|
|
G |
Smpd1 |
sphingomyelin phosphodiesterase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:24951586 |
|
NCBI chrNW_004624817:7,909,777...7,913,419
Ensembl chrNW_004624817:7,909,468...7,913,417
|
|
G |
Snai1 |
snail family transcriptional repressor 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22580338 PMID:24014025 |
|
NCBI chrNW_004624790:5,509,541...5,515,240
Ensembl chrNW_004624790:5,509,311...5,515,266
|
|
G |
Snai2 |
snail family transcriptional repressor 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22580338 |
|
NCBI chrNW_004624735:6,594,564...6,598,288
Ensembl chrNW_004624735:6,594,695...6,598,757
|
|
G |
Sod2 |
superoxide dismutase 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:10853026 PMID:11053990 PMID:15048980 PMID:15654357 PMID:21749277 PMID:22580338 More...
|
|
NCBI chrNW_004624855:3,260,800...3,271,864
Ensembl chrNW_004624855:3,260,809...3,271,367
|
|
G |
Sorl1 |
sortilin related receptor 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 |
|
NCBI chrNW_004624880:3,579,783...3,749,958
Ensembl chrNW_004624880:3,583,838...3,749,930
|
|
G |
Sox11 |
SRY-box transcription factor 11 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 |
|
NCBI chrNW_004624846:4,043,010...4,046,660
Ensembl chrNW_004624846:4,044,893...4,046,248
|
|
G |
Sox9 |
SRY-box transcription factor 9 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:32682831 |
|
NCBI chrNW_004624801:2,296,353...2,300,853
Ensembl chrNW_004624801:2,296,168...2,301,596
|
|
G |
Sp1 |
Sp1 transcription factor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26317792 PMID:35072892 |
|
NCBI chrNW_004624904:1,475,664...1,507,588
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:18844224 PMID:21291860 |
|
NCBI chrNW_004624842:2,212,561...2,260,514
Ensembl chrNW_004624842:2,211,020...2,230,132
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26101800 |
|
NCBI chrNW_004624795:1,648,235...1,680,788
Ensembl chrNW_004624795:1,648,080...1,681,200
|
|
G |
Sumo1 |
small ubiquitin like modifier 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15048980 |
|
NCBI chrNW_004624765:14,205,071...14,229,864
Ensembl chrNW_004624765:14,205,051...14,229,864
|
|
G |
Tbx15 |
T-box transcription factor 15 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 |
|
NCBI chrNW_004624772:14,483,951...14,611,602
Ensembl chrNW_004624772:14,482,948...14,611,452
|
|
G |
Tfpi2 |
tissue factor pathway inhibitor 2 |
|
ISO |
|
RGD |
PMID:11687973 |
RGD:11060269 |
NCBI chrNW_004624813:571,592...577,268
Ensembl chrNW_004624813:571,414...577,858
|
|
G |
Tgfb1 |
transforming growth factor beta 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:23992306 PMID:24727557 PMID:24793912 PMID:25884904 PMID:26896736 PMID:32745479 More...
|
|
NCBI chrNW_004624907:162,567...175,696
Ensembl chrNW_004624907:161,569...176,605
|
|
G |
Tgif1 |
TGFB induced factor homeobox 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:25791921 |
|
NCBI chrNW_004624770:13,506,501...13,515,388
Ensembl chrNW_004624770:13,508,409...13,516,457
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:1318976 |
|
NCBI chrNW_004624978:120,723...125,006
Ensembl chrNW_004624978:121,803...124,912
|
|
G |
Timp3 |
TIMP metallopeptidase inhibitor 3 |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:23109338 |
|
NCBI chrNW_004624750:1,776,197...1,817,279
Ensembl chrNW_004624750:1,775,744...1,817,385
|
|
G |
Tkt |
transketolase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15654357 |
|
NCBI chrNW_004624822:3,989,292...4,014,150
Ensembl chrNW_004624822:3,989,299...4,014,269
|
|
G |
Tln1 |
talin 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21291860 |
|
NCBI chrNW_004624868:5,061,108...5,095,433
Ensembl chrNW_004624868:5,061,290...5,095,661
|
|
G |
Tlr4 |
toll like receptor 4 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21473897 |
|
NCBI chrNW_004624760:17,596,516...17,608,955
Ensembl chrNW_004624760:17,598,630...17,609,120
|
|
G |
Tmem139 |
transmembrane protein 139 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 |
|
NCBI chrNW_004624800:11,468,362...11,470,732
Ensembl chrNW_004624800:11,468,819...11,470,751
|
|
G |
Tnf |
tumor necrosis factor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22199285 PMID:23431386 PMID:23899529 PMID:24613819 |
|
NCBI chrNW_004624754:24,623,059...24,625,647
Ensembl chrNW_004624754:24,623,425...24,625,531
|
|
G |
Tp53bp2 |
tumor protein p53 binding protein 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28650484 |
|
NCBI chrNW_004624835:5,744,973...5,790,840
Ensembl chrNW_004624835:5,744,543...5,790,603
|
|
G |
Trim47 |
tripartite motif containing 47 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:31981573 |
|
NCBI chrNW_004624801:5,761,584...5,765,866
Ensembl chrNW_004624801:5,761,584...5,765,873
|
|
G |
Trpm7 |
transient receptor potential cation channel subfamily M member 7 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:30710498 |
|
NCBI chrNW_004624731:9,490,885...9,588,255
Ensembl chrNW_004624731:9,491,157...9,588,346
|
|
G |
Twist1 |
twist family bHLH transcription factor 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22155737 |
|
NCBI chrNW_004624739:11,352,040...11,354,019
Ensembl chrNW_004624739:11,352,141...11,352,809
|
|
G |
Txn |
thioredoxin |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15048980 |
|
NCBI chrNW_004624758:1,318,108...1,329,011
Ensembl chrNW_004624758:1,318,529...1,329,011
|
|
G |
Ubqln1 |
ubiquilin 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:24747970 |
|
NCBI chrNW_004624809:6,434,842...6,487,442
Ensembl chrNW_004624809:6,436,658...6,487,251
|
|
G |
Vim |
vimentin |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27811057 |
|
NCBI chrNW_004624796:10,624,672...10,632,300
Ensembl chrNW_004624796:10,623,929...10,632,600
|
|
G |
Xpc |
XPC complex subunit, DNA damage recognition and repair factor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27777383 |
|
NCBI chrNW_004624872:1,438,673...1,467,206
Ensembl chrNW_004624872:1,438,769...1,466,642
|
|
G |
Xrcc3 |
X-ray repair cross complementing 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21283680 |
|
NCBI chrNW_004624734:1,216,641...1,223,860
Ensembl chrNW_004624734:1,217,549...1,223,280
|
|
G |
Yap1 |
Yes1 associated transcriptional regulator |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:34351699 |
|
NCBI chrNW_004624878:621,214...776,363
|
|
G |
Zbtb16 |
zinc finger and BTB domain containing 16 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 |
|
NCBI chrNW_004624784:9,545,529...9,726,960
Ensembl chrNW_004624784:9,546,509...9,726,960
|
|
G |
Zeb1 |
zinc finger E-box binding homeobox 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21954225 |
|
NCBI chrNW_004624805:3,964,448...4,044,546
Ensembl chrNW_004624805:3,964,450...4,042,527
|
|
G |
Zeb2 |
zinc finger E-box binding homeobox 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21954225 |
|
NCBI chrNW_004624732:44,097,348...44,226,701
Ensembl chrNW_004624732:44,101,613...44,139,997
|
|
G |
Zfp36 |
ZFP36 ring finger protein |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:25556371 |
|
NCBI chrNW_004624794:12,732,222...12,738,006
Ensembl chrNW_004624794:12,734,191...12,737,971
|
|
G |
Zfr |
zinc finger RNA binding protein |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:34323000 |
|
NCBI chrNW_004624759:22,135,431...22,207,283
Ensembl chrNW_004624759:22,135,358...22,207,442
|
|
G |
Znf367 |
zinc finger protein 367 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:34351699 |
|
NCBI chrNW_004624753:18,145,862...18,166,732
Ensembl chrNW_004624753:18,146,067...18,164,534
|
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 (PEL blood group) |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17003774 |
|
NCBI chrNW_004624879:1,811,686...2,060,221
Ensembl chrNW_004624879:1,811,651...2,060,099
|
|
G |
Ace |
angiotensin I converting enzyme |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:18059164 |
|
NCBI chrNW_004624849:998,262...1,019,305
Ensembl chrNW_004624849:998,277...1,019,521
|
|
G |
Ackr3 |
atypical chemokine receptor 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22180778 |
|
NCBI chrNW_004624847:2,189,167...2,200,355
Ensembl chrNW_004624847:2,189,257...2,200,352
|
|
G |
Acsbg1 |
acyl-CoA synthetase bubblegum family member 1 |
|
ISO |
associated with pheochromocytoma |
RGD |
PMID:29067245 |
RGD:13831131 |
NCBI chrNW_004624894:2,618,000...2,661,174
Ensembl chrNW_004624894:2,617,711...2,661,174
|
|
G |
Acvr2a |
activin A receptor type 2A |
exacerbates |
ISO |
associated with colon cancer;mRNA,protein:decreased expression:colon (human) |
RGD |
PMID:30310521 |
RGD:151361136 |
NCBI chrNW_004624866:539,967...619,575
Ensembl chrNW_004624866:539,894...620,302
|
|
G |
Adgrb1 |
adhesion G protein-coupled receptor B1 |
|
ISO |
associated with colorectal cancer |
RGD |
PMID:9772287 |
RGD:13831353 |
NCBI chrNW_004624735:14,049,621...14,126,287
Ensembl chrNW_004624735:14,050,213...14,113,534
|
|
G |
Adora2b |
adenosine A2b receptor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27590504 |
|
NCBI chrNW_004624877:4,421,307...4,447,574
Ensembl chrNW_004624877:4,422,022...4,447,460
|
|
G |
Agtr1 |
angiotensin II receptor type 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:18059164 |
|
NCBI chrNW_004624730:25,964,848...26,006,468
Ensembl chrNW_004624730:25,964,811...26,006,463
|
|
G |
Agtr2 |
angiotensin II receptor type 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:18059164 |
|
NCBI chrNW_004624967:327,627...332,000
Ensembl chrNW_004624967:329,284...330,372
|
|
G |
Ahr |
aryl hydrocarbon receptor |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:21948867 |
|
NCBI chrNW_004624739:12,939,183...12,987,574
Ensembl chrNW_004624739:12,942,165...12,987,973
|
|
G |
Akirin2 |
akirin 2 |
|
ISO |
|
RGD |
PMID:18460465 |
RGD:2306009 |
NCBI chrNW_004624799:6,620,102...6,644,286
Ensembl chrNW_004624799:6,625,549...6,644,286
|
|
G |
Akt2 |
AKT serine/threonine kinase 2 |
|
ISO |
associated with Mammary Neoplasms, Experimental |
RGD |
PMID:19491266 |
RGD:2315599 |
NCBI chrNW_004624925:262,590...322,440
Ensembl chrNW_004624925:273,881...326,984
|
|
G |
Alk |
ALK receptor tyrosine kinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22986231 PMID:22999080 |
|
NCBI chrNW_004624738:11,094,699...12,010,349
Ensembl chrNW_004624738:11,095,134...11,288,891
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20061081 |
|
NCBI chrNW_004624966:168,244...220,430
Ensembl chrNW_004624966:168,250...220,522
|
|
G |
Amigo2 |
adhesion molecule with Ig like domain 2 |
|
ISO |
Liver Metastasis |
RGD |
PMID:28272394 |
RGD:14394499 |
NCBI chrNW_004624816:5,184,423...5,189,691
Ensembl chrNW_004624816:5,184,536...5,187,659
|
|
G |
Angptl4 |
angiopoietin like 4 |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:17130448 |
|
NCBI chrNW_004624828:1,152,788...1,158,864
Ensembl chrNW_004624828:1,152,891...1,158,420
|
|
G |
Antxr1 |
ANTXR cell adhesion molecule 1 |
|
ISO |
associated with Mammary Neoplasms, Experimental; |
RGD |
PMID:22085271 |
RGD:9684855 |
NCBI chrNW_004624762:4,051,479...4,377,237
Ensembl chrNW_004624762:4,128,127...4,377,278
|
|
G |
Anxa1 |
annexin A1 |
treatment |
ISO |
associated with Mammary Neoplasms, Experimental CTD Direct Evidence: marker/mechanism associated with Mammary Neoplasms, Experimental;protein:increased expression:lung |
RGD CTD |
PMID:9514092 PMID:20308542 PMID:20821804 |
RGD:2306939 RGD:7421541 RGD:7421563 |
NCBI chrNW_004624811:765,338...782,203
Ensembl chrNW_004624811:764,940...782,198
|
|
G |
Anxa4 |
annexin A4 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17085005 |
|
NCBI chrNW_004624762:3,562,656...3,641,465
Ensembl chrNW_004624762:3,562,446...3,641,770
|
|
G |
Anxa7 |
annexin A7 |
|
ISO |
associated with Prostatic Neoplasms;protein:decreased expression:prostate gland associated with Breast Neoplasms;protein:increased expression:breast |
RGD |
PMID:11287641 PMID:15073110 |
RGD:2292655 RGD:2292656 |
NCBI chrNW_004624754:6,992,436...7,022,419
|
|
G |
Apoe |
apolipoprotein E |
|
ISO |
|
RGD |
PMID:22469977 |
RGD:7771597 |
NCBI chrNW_004624907:1,752,322...1,755,308
|
|
G |
Arhgdia |
Rho GDP dissociation inhibitor alpha |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20562527 |
|
NCBI chrNW_004624801:10,719,987...10,723,263
Ensembl chrNW_004624801:10,717,133...10,722,840
|
|
G |
Arid1a |
AT-rich interaction domain 1A |
disease_progression |
ISO |
in lung; associated with hepatocellular carcinoma |
RGD |
PMID:25975202 |
RGD:125097495 |
NCBI chrNW_004624764:10,672,673...10,759,634
Ensembl chrNW_004624764:10,672,735...10,759,634
|
|
G |
Atp6v1c1 |
ATPase H+ transporting V1 subunit C1 |
|
ISO |
associated with Mammary Neoplasms, Experimental |
RGD |
PMID:24155661 |
RGD:14700647 |
NCBI chrNW_004624763:19,726,883...19,769,247
Ensembl chrNW_004624763:19,726,841...19,769,372
|
|
G |
Axl |
AXL receptor tyrosine kinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26206560 |
|
NCBI chrNW_004624907:76,236...106,765
Ensembl chrNW_004624907:77,806...106,228
|
|
G |
Azin1 |
antizyme inhibitor 1 |
|
ISO |
associated with colorectal cancer;RNA:increased editing:colorectum associated with stomach cancer;RNA:increased editing:stomach |
RGD |
PMID:29925690 PMID:30563560 |
RGD:14700703 RGD:14700704 |
NCBI chrNW_004624763:19,643,980...19,667,125
Ensembl chrNW_004624763:19,643,980...19,667,125
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
|
ISO |
associated with Carcinoma, Infiltrating Duct |
RGD |
PMID:17288732 |
RGD:1643356 |
NCBI chrNW_004624832:5,050,222...5,068,565
Ensembl chrNW_004624832:5,050,222...5,055,506
|
|
G |
Bcl2 |
BCL2 apoptosis regulator |
|
ISO |
associated with Carcinoma, Renal Cell associated with Breast Neoplasms |
RGD |
PMID:12810203 PMID:16826579 |
RGD:2293020 RGD:2293021 |
NCBI chrNW_004624792:8,854,345...9,032,727
Ensembl chrNW_004624792:8,859,522...9,031,344
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
severity |
ISO |
associated with Prostatic Neoplasms;protein:increased expression:bone |
RGD |
PMID:16166304 |
RGD:2289018 |
NCBI chrNW_004624756:17,742,822...17,894,931
Ensembl chrNW_004624756:17,743,834...17,894,753
|
|
G |
Bmp7 |
bone morphogenetic protein 7 |
disease_progression |
ISO |
associated with Breast Neoplasms;protein:increased expression:breast associated with Prostatic Neoplasms;mRNA:increased expression:bone |
RGD |
PMID:12539225 PMID:17895257 |
RGD:2289029 RGD:2289033 |
NCBI chrNW_004624741:23,658,214...23,743,227
Ensembl chrNW_004624741:23,658,004...23,737,742
|
|
G |
Braf |
B-Raf proto-oncogene, serine/threonine kinase |
onset |
ISO |
associated with Melanoma; DNA:mutations: : |
RGD |
PMID:25623140 |
RGD:11567259 |
NCBI chrNW_004624765:20,766,368...20,951,560
Ensembl chrNW_004624765:20,773,885...20,951,736
|
|
G |
Brd4 |
bromodomain containing 4 |
|
ISO |
|
RGD |
PMID:23950209 |
RGD:9586346 |
NCBI chrNW_004624901:2,348,218...2,434,429
Ensembl chrNW_004624901:2,346,734...2,380,852
|
|
G |
Brms1 |
BRMS1 transcriptional repressor and anoikis regulator |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:27501413 |
|
NCBI chrNW_004624767:20,036,190...20,043,871
Ensembl chrNW_004624767:20,036,256...20,043,876
|
|
G |
Bsg |
basigin (Ok blood group) |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21956400 |
|
NCBI chrNW_004624828:7,913,297...7,920,891
Ensembl chrNW_004624828:7,913,099...7,920,804
|
|
G |
Cab39 |
calcium binding protein 39 |
|
ISO |
associated with hepatocellular carcinoma; |
RGD |
PMID:28605041 |
RGD:14398832 |
NCBI chrNW_004624843:4,129,755...4,217,406
Ensembl chrNW_004624843:4,130,052...4,217,540
|
|
G |
Cacybp |
calcyclin binding protein |
|
ISO |
associated with pancreatic neoplasms |
RGD |
PMID:18765951 |
RGD:2326146 |
NCBI chrNW_004624771:6,982,248...6,993,661
Ensembl chrNW_004624771:6,982,255...6,993,867
|
|
G |
Calml3 |
calmodulin like 3 |
ameliorates |
ISO |
associated with hepatocellular carcinoma; human cells in mouse model associated with hepatocellular carcinoma; protein:decreased expression:liver (human) |
RGD |
PMID:29445139 |
RGD:151665319 |
NCBI chrNW_004624775:335,860...338,267
Ensembl chrNW_004624775:337,054...337,503
|
|
G |
Cap1 |
cyclase associated actin cytoskeleton regulatory protein 1 |
|
ISO |
associated with Pancreatic Neoplasms; mRNA, protein:increased expression:pancreas |
RGD |
PMID:19188911 |
RGD:2326238 |
NCBI chrNW_004624764:22,517,254...22,542,356
Ensembl chrNW_004624764:22,517,315...22,542,351
|
|
G |
Cat |
catalase |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:12538496 PMID:22580338 PMID:23518002 |
|
NCBI chrNW_004624767:12,680,940...12,715,468
Ensembl chrNW_004624767:12,680,953...12,715,739
|
|
G |
Cav1 |
caveolin 1 |
treatment |
ISO |
associated with Mammary Neoplasms, Experimental CTD Direct Evidence: marker/mechanism |
RGD CTD |
PMID:15334058 PMID:15355971 PMID:20562527 |
RGD:2289106 RGD:8661780 |
NCBI chrNW_004624827:2,844,855...2,878,367
Ensembl chrNW_004624827:2,844,115...2,879,179
|
|
G |
Cbx4 |
chromobox 4 |
|
ISO |
associated with Carcinoma, Hepatocellular; |
RGD |
PMID:24838576 |
RGD:9586738 |
NCBI chrNW_004624801:9,002,290...9,008,305
Ensembl chrNW_004624801:9,003,059...9,008,203
|
|
G |
Cbx5 |
chromobox 5 |
|
ISO |
associated with Lung Neoplasms; |
RGD |
PMID:22900142 |
RGD:9586743 |
NCBI chrNW_004624904:2,273,054...2,313,723
Ensembl chrNW_004624904:2,276,036...2,296,706
|
|
G |
Ccl20 |
C-C motif chemokine ligand 20 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:30603057 |
|
NCBI chrNW_004624843:2,017,738...2,021,153
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
treatment |
ISO |
associated with Animal Mammary Neoplasms; |
RGD |
PMID:15692764 |
RGD:14995455 |
NCBI chrNW_004624875:3,334,136...3,342,085
Ensembl chrNW_004624875:3,334,078...3,341,614
|
|
G |
Ccn4 |
cellular communication network factor 4 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:30723155 |
|
NCBI chrNW_004624735:22,789,784...22,819,527
Ensembl chrNW_004624735:22,788,475...22,819,648
|
|
G |
Ccna2 |
cyclin A2 |
|
ISO |
associated with Seminoma;protein:increased expression:testis |
RGD |
PMID:14696091 |
RGD:2293346 |
NCBI chrNW_004624777:2,097,002...2,104,244
|
|
G |
Ccnd1 |
cyclin D1 |
treatment |
ISO |
associated with stomach cancer; human cells in mouse model associated with Carcinoma, Non-Small-Cell Lung;mRNA:splice variant |
RGD |
PMID:18715616 PMID:27431311 |
RGD:13434926 RGD:152995400 |
NCBI chrNW_004624767:17,470,310...17,483,082
Ensembl chrNW_004624767:17,469,622...17,483,191
|
|
G |
Ccnd2 |
cyclin D2 |
|
ISO |
associated with Breast Neoplasms;DNA:hypermethylated:brain |
RGD |
PMID:15131050 |
RGD:2289155 |
NCBI chrNW_004624860:1,383,015...1,405,107
Ensembl chrNW_004624860:1,382,948...1,405,107
|
|
G |
Ccne1 |
cyclin E1 |
disease_progression |
ISO |
associated with non-small cell lung carcinoma protein:altered processing |
RGD |
PMID:11212263 PMID:17671189 |
RGD:13673913 RGD:2289229 |
NCBI chrNW_004624794:4,957,156...4,967,058
Ensembl chrNW_004624794:4,957,178...4,967,140
|
|
G |
Cd274 |
CD274 molecule |
disease_progression |
ISO |
associated with ovarian cancer |
RGD |
PMID:23340297 |
RGD:41410797 |
NCBI chrNW_004624736:9,991,851...10,017,047
Ensembl chrNW_004624736:9,996,156...10,013,814
|
|
G |
Cd44 |
CD44 molecule (IN blood group) |
|
ISO |
associated with Carcinoma, Renal Cell;protein:increased expression:kidney CTD Direct Evidence: marker/mechanism |
RGD CTD |
PMID:18026989 PMID:23098472 |
RGD:2289347 |
NCBI chrNW_004624767:11,938,452...12,024,970
Ensembl chrNW_004624767:11,938,028...12,025,069
|
|
G |
Cd82 |
CD82 molecule |
|
ISO |
associated with Carcinoma, Infiltrating Duct;mRNA:decreased expression:brain associated with Prostatic Neoplasms;mRNA:decreased expression associated with Carcinoma, Hepatocellular;mRNA:decreased expression associated with Prostatic Neoplasms;mRNA:decreased expression:bone associated with Prostatic Neoplasms;DNA:loss of heterozygosity CTD Direct Evidence: therapeutic |
RGD CTD |
PMID:9254900 PMID:9831222 PMID:11275982 PMID:12806379 PMID:15592684 PMID:20075392 More...
|
RGD:2289400 RGD:2289402 RGD:2289407 RGD:2289425 RGD:68869 |
NCBI chrNW_004624767:3,556,128...3,589,956
|
|
G |
Cd86 |
CD86 molecule |
|
ISO |
mRNA:decreased expression:mediastinal lymph node (rat) |
RGD |
PMID:18360875 |
RGD:4892237 |
NCBI chrNW_004624912:350,201...432,410
Ensembl chrNW_004624912:350,157...426,712
|
|
G |
Cdh1 |
cadherin 1 |
treatment |
ISO |
CTD Direct Evidence: marker/mechanism associated with Prostatic Neoplasms associated with stomach cancer; human cells in mouse model |
CTD RGD |
PMID:17520682 PMID:18008331 PMID:22580338 PMID:27431311 |
RGD:152995400 RGD:2289488 |
NCBI chrNW_004624746:17,480,472...17,557,722
Ensembl chrNW_004624746:17,483,469...17,557,581
|
|
G |
Cdh2 |
cadherin 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:23876460 |
|
NCBI chrNW_004624770:4,333,643...4,540,817
Ensembl chrNW_004624770:4,334,202...4,545,470
|
|
G |
Cdkl2 |
cyclin dependent kinase like 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:25333262 |
|
NCBI chrNW_004624730:219,722...279,866
Ensembl chrNW_004624730:219,730...277,898
|
|
G |
Cdkn1a |
cyclin dependent kinase inhibitor 1A |
|
ISO |
associated with Melanoma; |
RGD |
PMID:9194578 |
RGD:8662817 |
NCBI chrNW_004624754:21,109,074...21,115,869
Ensembl chrNW_004624754:21,108,874...21,115,885
|
|
G |
Cfl1 |
cofilin 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20562527 |
|
NCBI chrNW_004624767:20,574,884...20,578,413
Ensembl chrNW_004624767:20,574,966...20,579,796
|
|
G |
Cga |
glycoprotein hormones, alpha polypeptide |
|
ISO |
associated with Breast Neoplasms;protein:increased expression:serum |
RGD |
PMID:6768680 |
RGD:2293637 |
NCBI chrNW_004624799:7,249,502...7,265,662
Ensembl chrNW_004624799:7,249,586...7,265,999
|
|
G |
Chek1 |
checkpoint kinase 1 |
|
ISO |
associated with Pancreatic Neoplasms |
RGD |
PMID:15448002 |
RGD:2317235 |
NCBI chrNW_004624927:1,609,404...1,643,409
Ensembl chrNW_004624927:1,610,878...1,643,409
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
|
ISO |
associated with prostate adenocarcinoma |
RGD |
PMID:17377533 |
RGD:2298657 |
NCBI chrNW_004624737:12,022,081...12,052,128
Ensembl chrNW_004624737:12,022,419...12,052,131
|
|
G |
Cic |
capicua transcriptional repressor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27869830 |
|
NCBI chrNW_004624907:458,447...486,482
Ensembl chrNW_004624907:454,948...486,565
|
|
G |
Cldn7 |
claudin 7 |
|
ISO |
|
RGD |
PMID:23390083 |
RGD:9685143 |
NCBI chrNW_004624786:9,873,555...9,875,743
Ensembl chrNW_004624786:9,873,555...9,875,817
|
|
G |
Clic1 |
chloride intracellular channel 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20562527 |
|
NCBI chrNW_004624754:24,476,262...24,482,529
Ensembl chrNW_004624754:24,476,213...24,482,529
|
|
G |
Clu |
clusterin |
|
ISO |
associated with Breast Neoplasms |
RGD |
PMID:20307318 |
RGD:8883512 |
NCBI chrNW_004624758:22,431,331...22,444,185
Ensembl chrNW_004624758:22,426,918...22,444,357
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:29179997 |
|
NCBI chrNW_004624765:8,374,160...8,436,969
|
|
G |
Csf1 |
colony stimulating factor 1 |
|
ISO |
associated with Prostatic Neoplasms |
RGD |
PMID:18510570 |
RGD:2293638 |
NCBI chrNW_004624772:5,663,374...5,705,965
Ensembl chrNW_004624772:5,663,070...5,707,753
|
|
G |
Csf1r |
colony stimulating factor 1 receptor |
exacerbates |
ISO |
associated with Prostatic Neoplasms associated with breast cancer CTD Direct Evidence: marker/mechanism |
RGD CTD |
PMID:1390197 PMID:18510570 PMID:25005824 |
RGD:150524287 RGD:2293638 |
NCBI chrNW_004624774:9,363,156...9,391,939
Ensembl chrNW_004624774:9,363,908...9,391,986
|
|
G |
Csf3 |
colony stimulating factor 3 |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:7543699 PMID:9018096 |
|
NCBI chrNW_004624795:3,162,999...3,167,248
Ensembl chrNW_004624795:3,163,009...3,166,594
|
|
G |
Csta |
cystatin A |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20461718 |
|
NCBI chrNW_004624912:657,771...671,304
Ensembl chrNW_004624912:657,774...671,329
|
|
G |
Ctla4 |
cytotoxic T-lymphocyte associated protein 4 |
disease_progression |
ISO |
associated with Mammary Neoplasms, Experimental |
RGD |
PMID:15701862 PMID:18049334 |
RGD:4891518 RGD:7204722 |
NCBI chrNW_004624765:12,449,205...12,454,324
Ensembl chrNW_004624765:12,449,205...12,454,324
|
|
G |
Ctnnb1 |
catenin beta 1 |
|
ISO |
associated with Prostatic Neoplasms CTD Direct Evidence: marker/mechanism |
RGD CTD |
PMID:18008331 PMID:29106415 |
RGD:2289488 |
NCBI chrNW_004624730:77,876,361...77,887,228
Ensembl chrNW_004624730:77,875,257...77,887,234
|
|
G |
Ctsb |
cathepsin B |
|
ISO |
protein:increased expression:cerebrospinal fluid |
RGD |
PMID:12589965 |
RGD:5686394 |
NCBI chrNW_004624758:25,366,120...25,384,554
Ensembl chrNW_004624758:25,366,840...25,373,954
|
|
G |
Ctsd |
cathepsin D |
|
ISO |
protein:increased expression:oral cavity, oropharynx, hypopharynx (human) |
RGD |
PMID:10562684 |
RGD:1547892 |
NCBI chrNW_004624767:14,661,058...14,671,116
Ensembl chrNW_004624767:14,660,936...14,671,671
|
|
G |
Ctsh |
cathepsin H |
|
ISO |
protein:increased expression:cerebrospinal fluid |
RGD |
PMID:12589965 |
RGD:5686394 |
NCBI chrNW_004624941:82,209...98,156
Ensembl chrNW_004624941:82,209...98,182
|
|
G |
Ctu1 |
cytosolic thiouridylase subunit 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27811057 |
|
NCBI chrNW_004624832:3,433,809...3,438,847
|
|
G |
Ctu2 |
cytosolic thiouridylase subunit 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27811057 |
|
NCBI chrNW_004624746:871,707...878,047
Ensembl chrNW_004624746:871,668...877,719
|
|
G |
Cx3cr1 |
C-X3-C motif chemokine receptor 1 |
susceptibility |
ISO |
associated with Breast Neoplasms |
RGD |
PMID:16627550 |
RGD:4892015 |
NCBI chrNW_004624731:1,705,953...1,719,452
Ensembl chrNW_004624731:1,706,043...1,719,452
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
treatment |
ISO |
CTD Direct Evidence: marker/mechanism associated with Pancreatic Neoplasms associated with Pancreatic Carcinoma |
CTD RGD |
PMID:12761880 PMID:21312072 PMID:23743303 PMID:26330165 |
RGD:10398726 RGD:2317610 |
NCBI chrNW_004624922:1,261,228...1,273,755
Ensembl chrNW_004624922:1,261,228...1,273,758
|
|
G |
Cxcr3 |
C-X-C motif chemokine receptor 3 |
|
ISO |
associated with Mammary Neoplasms, Experimental |
RGD |
PMID:16885372 |
RGD:5135487 |
NCBI chrNW_004624903:1,958,323...1,961,789
Ensembl chrNW_004624903:1,958,698...1,961,763
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
disease_progression ameliorates severity |
ISO |
associated with lung non-small cell carcinoma; protein:increased expression:lung (human) associated with Otorhinolaryngologic Neoplasms;mRNA,protein:increased expression:Laryngeal and hypopharyngeal tissue (human) associated with oral squamous cell carcinoma CTD Direct Evidence: marker/mechanism associated with lung non-small cell carcinoma;mRNA,protein:increased expression:lung (human) associated with pancreatic cancer associated with osteosarcoma;protein:increased expression:bone (human) human cells in mouse model;associated with lung cancer associated with lung cancer; human cells in mouse model |
RGD CTD |
PMID:16230077 PMID:16322285 PMID:17634424 PMID:18487224 PMID:21312072 PMID:23743303 PMID:24932250 PMID:25504108 PMID:26546437 PMID:28000861 PMID:32037613 More...
|
RGD:151708730 RGD:152023741 RGD:152023745 RGD:152023746 RGD:152025556 RGD:152177475 RGD:152177476 RGD:152177478 RGD:152177479 |
NCBI chrNW_004624732:35,473,740...35,477,482
Ensembl chrNW_004624732:35,472,760...35,477,528
|
|
G |
Dab2ip |
DAB2 interacting protein |
severity |
ISO |
associated with colorectal cancer;protein:decreased expression:colorectum (human) |
RGD |
PMID:26336990 |
RGD:11531913 |
NCBI chrNW_004624760:13,472,500...13,658,070
Ensembl chrNW_004624760:13,472,672...13,657,930
|
|
G |
Dapk1 |
death associated protein kinase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17319784 |
|
NCBI chrNW_004624809:9,585,426...9,794,582
Ensembl chrNW_004624809:9,586,225...9,793,208
|
|
G |
Daxx |
death domain associated protein |
|
ISO |
|
RGD |
PMID:23539629 |
RGD:9587820 |
NCBI chrNW_004624754:23,504,465...23,509,034
Ensembl chrNW_004624754:23,505,386...23,509,241
|
|
G |
Dcn |
decorin |
|
ISO |
associated with Breast Neoplasms |
RGD |
PMID:18688028 |
RGD:2311418 |
NCBI chrNW_004624750:15,466,938...15,517,475
Ensembl chrNW_004624750:15,470,968...15,516,365
|
|
G |
Ddr1 |
discoidin domain receptor tyrosine kinase 1 |
severity |
ISO |
mRNA:increased expression:ovary (human) protein:increased expression:bone (human) |
RGD |
PMID:28743276 PMID:29039472 |
RGD:151347541 RGD:151347601 |
NCBI chrNW_004624754:24,881,439...24,905,633
Ensembl chrNW_004624754:24,880,496...24,896,995
|
|
G |
Ddr2 |
discoidin domain receptor tyrosine kinase 2 |
ameliorates |
ISO |
associated with melanoma; |
RGD |
PMID:24293323 |
RGD:150429711 |
NCBI chrNW_004624826:1,225,217...1,255,889
Ensembl chrNW_004624826:1,173,621...1,249,692
|
|
G |
Ddx3x |
DEAD-box helicase 3 X-linked |
|
ISO |
human cells in mouse model |
RGD |
PMID:26087195 |
RGD:11096798 |
NCBI chrNW_004624762:14,290,267...14,305,437
Ensembl chrNW_004624762:14,290,267...14,305,633
|
|
G |
Dek |
DEK proto-oncogene |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27811057 |
|
NCBI chrNW_004624756:8,421,492...8,447,452
Ensembl chrNW_004624756:8,421,782...8,447,452
|
|
G |
Dhfr |
dihydrofolate reductase |
disease_progression |
ISO |
CTD Direct Evidence: marker/mechanism |
RGD CTD |
PMID:8149482 PMID:19159907 |
RGD:11040442 |
NCBI chrNW_004624743:1,446,643...1,462,319
Ensembl chrNW_004624743:1,446,643...1,461,863
|
|
G |
Dio3 |
iodothyronine deiodinase 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26825960 |
|
NCBI chrNW_004624734:2,611,864...2,613,932
|
|
G |
Dmd |
dystrophin |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:24793134 |
|
NCBI chrNW_004624762:22,306,962...24,846,427
Ensembl chrNW_004624762:22,746,729...24,847,938
|
|
G |
Dnmt3b |
DNA methyltransferase 3 beta |
|
ISO |
associated with Uterine Cervical Neoplasms; |
RGD |
PMID:22330137 |
RGD:9589117 |
NCBI chrNW_004624842:6,450,972...6,505,929
Ensembl chrNW_004624842:6,450,852...6,475,785
|
|
G |
E2f1 |
E2F transcription factor 1 |
severity |
ISO |
protein:increased expression:bone (human) |
RGD |
PMID:29039472 |
RGD:151347601 |
NCBI chrNW_004624842:5,602,432...5,612,951
Ensembl chrNW_004624842:5,602,432...5,612,951
|
|
G |
E2f8 |
E2F transcription factor 8 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27683099 |
|
NCBI chrNW_004624766:10,652,749...10,670,886
Ensembl chrNW_004624766:10,652,745...10,669,909
|
|
G |
Edn1 |
endothelin 1 |
|
ISO |
|
RGD |
PMID:12941866 |
RGD:734914 |
NCBI chrNW_004624756:13,842,482...13,849,003
Ensembl chrNW_004624756:13,842,164...13,849,029
|
|
G |
Ednra |
endothelin receptor type A |
|
ISO |
associated with Bladder Neoplasms |
RGD |
PMID:21183790 |
RGD:4892282 |
NCBI chrNW_004624853:6,298,406...6,362,353
Ensembl chrNW_004624853:6,302,751...6,360,089
|
|
G |
Eef1b2 |
eukaryotic translation elongation factor 1 beta 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17085005 PMID:20562527 |
|
NCBI chrNW_004624765:9,958,908...9,962,074
Ensembl chrNW_004624765:9,958,907...9,962,108
|
|
G |
Eef2 |
eukaryotic translation elongation factor 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20562527 |
|
NCBI chrNW_004624828:5,601,906...5,609,978
Ensembl chrNW_004624828:5,601,444...5,611,405
|
|
G |
Efnb2 |
ephrin B2 |
|
ISO |
associated with cholangiocarcinoma;protein:increased expression:biliary ductule (human) |
RGD |
PMID:25012246 |
RGD:153305948 |
NCBI chrNW_004624793:5,089,675...5,130,022
Ensembl chrNW_004624793:5,089,639...5,130,503
|
|
G |
Egfr |
epidermal growth factor receptor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17369752 PMID:17575224 PMID:23867902 |
|
NCBI chrNW_004624740:584,133...713,205
Ensembl chrNW_004624740:589,606...713,271
|
|
G |
Ehmt2 |
euchromatic histone lysine methyltransferase 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism associated with lung neoplasms; |
CTD RGD |
PMID:20940408 PMID:25115793 |
RGD:9589170 |
NCBI chrNW_004624754:24,354,271...24,368,319
Ensembl chrNW_004624754:24,354,284...24,368,638
|
|
G |
Eif1ax |
eukaryotic translation initiation factor 1A X-linked |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17085005 |
|
NCBI chrNW_004624829:4,954,390...4,972,934
Ensembl chrNW_004624829:4,957,809...4,973,220
|
|
G |
Eif4a2 |
eukaryotic translation initiation factor 4A2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17085005 |
|
NCBI chrNW_004624730:69,999,879...70,006,008
Ensembl chrNW_004624730:69,996,219...70,005,910
|
|
G |
Elp3 |
elongator acetyltransferase complex subunit 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27811057 |
|
NCBI chrNW_004624758:22,838,077...22,904,627
Ensembl chrNW_004624758:22,837,374...22,903,714
|
|
G |
Eml4 |
EMAP like 4 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22986231 PMID:22999080 |
|
NCBI chrNW_004624738:23,887,822...24,045,864
Ensembl chrNW_004624738:23,887,782...24,048,204
|
|
G |
Enpp2 |
ectonucleotide pyrophosphatase/phosphodiesterase 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26037280 |
|
NCBI chrNW_004624763:17,677,825...17,775,284
Ensembl chrNW_004624763:17,677,722...17,765,292
|
|
G |
Epcam |
epithelial cell adhesion molecule |
|
ISO |
|
RGD |
PMID:23390083 |
RGD:9685143 |
NCBI chrNW_004624738:28,755,039...28,770,160
Ensembl chrNW_004624738:28,754,602...28,770,758
|
|
G |
Epor |
erythropoietin receptor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:16699298 |
|
NCBI chrNW_004624828:3,181,772...3,187,242
Ensembl chrNW_004624828:3,181,957...3,187,231
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism rat gene in a mouse model |
CTD RGD |
PMID:11238891 PMID:16984552 |
RGD:734938 |
NCBI chrNW_004624795:3,373,313...3,391,509
Ensembl chrNW_004624795:3,373,000...3,391,602
|
|
G |
Erbb3 |
erb-b2 receptor tyrosine kinase 3 |
disease_progression |
ISO |
associated with Prostatic Neoplasms;protein:alternative form associated with lung adenocarcinoma CTD Direct Evidence: marker/mechanism associated with Prostatic Neoplasms;protein:increased expression, altered localization:bone, nucleus |
RGD CTD |
PMID:17634423 PMID:18559590 PMID:26254096 PMID:28114269 |
RGD:126790470 RGD:2289944 RGD:2298500 |
NCBI chrNW_004624802:11,906,279...11,925,530
Ensembl chrNW_004624802:11,905,271...11,925,707
|
|
G |
Erbb4 |
erb-b2 receptor tyrosine kinase 4 |
disease_progression |
ISO |
associated with lung adenocarcinoma |
RGD |
PMID:26254096 |
RGD:126790470 |
NCBI chrNW_004624765:3,612,781...4,742,219
Ensembl chrNW_004624765:3,613,379...4,734,585
|
|
G |
Ercc1 |
ERCC excision repair 1, endonuclease non-catalytic subunit |
disease_progression |
ISO |
associated with Melanoma CTD Direct Evidence: marker/mechanism |
RGD CTD |
PMID:20801905 PMID:26202595 |
RGD:11252177 |
NCBI chrNW_004624907:2,288,380...2,298,909
Ensembl chrNW_004624907:2,288,423...2,298,373
|
|
G |
Ercc4 |
ERCC excision repair 4, endonuclease catalytic subunit |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20372803 |
|
NCBI chrNW_004624782:4,508,758...4,537,751
Ensembl chrNW_004624782:4,512,650...4,537,701
|
|
G |
Erp29 |
endoplasmic reticulum protein 29 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17085005 |
|
NCBI chrNW_004624747:20,167,197...20,174,914
Ensembl chrNW_004624747:20,166,371...20,175,012
|
|
G |
Esr1 |
estrogen receptor 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20104649 PMID:35044086 |
|
NCBI chrNW_004624785:6,164,507...6,601,302
Ensembl chrNW_004624785:6,164,379...6,601,326
|
|
G |
Etv4 |
ETS variant transcription factor 4 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27869830 |
|
NCBI chrNW_004624795:1,079,024...1,090,364
Ensembl chrNW_004624795:1,079,537...1,089,964
|
|
G |
Ezh2 |
enhancer of zeste 2 polycomb repressive complex 2 subunit |
|
ISO |
associated with lung non-small cell carcinoma associated with stomach cancer;protein:increased expression:stomach associated with osteosarcoma |
RGD |
PMID:20132185 PMID:24097870 PMID:26265454 |
RGD:11532507 RGD:126779607 RGD:126781716 |
NCBI chrNW_004624800:6,781,848...6,874,221
Ensembl chrNW_004624800:6,802,901...6,874,196
|
|
G |
Ezr |
ezrin |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27137931 |
|
NCBI chrNW_004624929:827,275...873,743
Ensembl chrNW_004624929:826,531...873,572
|
|
G |
F2 |
coagulation factor II, thrombin |
|
ISO |
associated with Carcinoma, Small cell;protein:increased expression:brain |
RGD |
PMID:22065054 |
RGD:6893520 |
NCBI chrNW_004624767:1,876,974...1,887,720
Ensembl chrNW_004624767:1,877,024...1,887,958
|
|
G |
Fadd |
Fas associated via death domain |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:16450001 |
|
NCBI chrNW_004624767:17,050,929...17,059,648
Ensembl chrNW_004624767:17,055,509...17,059,705
|
|
G |
Fas |
Fas cell surface death receptor |
|
ISO |
associated with Breast Neoplasms;protein:decreased expression:breast associated with Mammary Neoplasms;protein:decreased expression:lung |
RGD |
PMID:17352235 PMID:17918178 |
RGD:2290048 RGD:2290053 |
NCBI chrNW_004624791:15,290,022...15,315,848
Ensembl chrNW_004624791:15,289,348...15,315,848
|
|
G |
Faslg |
Fas ligand |
|
ISO |
associated with Breast Neoplasms;protein:decreased expression:breast |
RGD |
PMID:17352235 |
RGD:2290053 |
NCBI chrNW_004624771:9,031,978...9,038,760
Ensembl chrNW_004624771:9,032,016...9,038,825
|
|
G |
Fgf13 |
fibroblast growth factor 13 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19917848 |
|
NCBI chrNW_004624808:7,577,422...8,091,216
Ensembl chrNW_004624808:7,578,286...8,091,811
|
|
G |
Fgfr1 |
fibroblast growth factor receptor 1 |
|
ISO |
associated with prostate adenocarcinoma |
RGD |
PMID:23576558 |
RGD:13504748 |
NCBI chrNW_004624780:5,161,245...5,212,641
Ensembl chrNW_004624780:5,161,073...5,213,870
|
|
G |
Flt1 |
fms related receptor tyrosine kinase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21975929 |
|
NCBI chrNW_004624776:10,043,113...10,218,598
Ensembl chrNW_004624776:10,043,258...10,219,104
|
|
G |
Fn1 |
fibronectin 1 |
treatment |
ISO |
associated with stomach cancer; human cells in mouse model |
RGD |
PMID:27431311 |
RGD:152995400 |
NCBI chrNW_004624765:707,872...775,056
Ensembl chrNW_004624765:707,755...775,056
|
|
G |
Fscn1 |
fascin actin-bundling protein 1 |
|
ISO |
associated with Pancreatic Neoplasms |
RGD |
PMID:15626919 |
RGD:2317788 |
NCBI chrNW_004624740:28,038,216...28,047,252
Ensembl chrNW_004624740:28,036,731...28,047,364
|
|
G |
Ftl |
ferritin light chain |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17085005 |
|
NCBI chrNW_004624832:5,046,207...5,047,828
Ensembl chrNW_004624832:5,046,208...5,047,828
|
|
G |
Gab2 |
GRB2 associated binding protein 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21996746 |
|
NCBI chrNW_004624863:1,216,664...1,410,934
Ensembl chrNW_004624863:1,219,866...1,281,847
|
|
G |
Gdf15 |
growth differentiation factor 15 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:23996089 |
|
NCBI chrNW_004624908:1,633,927...1,636,242
Ensembl chrNW_004624908:1,634,174...1,636,242
|
|
G |
Gjb1 |
gap junction protein beta 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17978847 |
|
NCBI chrNW_004624903:1,511,347...1,519,265
Ensembl chrNW_004624903:1,517,324...1,519,265
|
|
G |
Gp1ba |
glycoprotein Ib platelet subunit alpha |
|
ISO |
associated with Melanoma, Experimental |
RGD |
PMID:19727118 |
RGD:10450866 |
NCBI chrNW_004624786:8,789,496...8,794,897
|
|
G |
Gpcpd1 |
glycerophosphocholine phosphodiesterase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:25482527 |
|
NCBI chrNW_004624741:6,472,558...6,529,698
Ensembl chrNW_004624741:6,472,558...6,528,865
|
|
G |
Gpi |
glucose-6-phosphate isomerase |
|
ISO |
|
RGD |
PMID:20978190 |
RGD:11051956 |
NCBI chrNW_004624794:8,826,281...8,851,614
Ensembl chrNW_004624794:8,823,449...8,851,625
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:23867582 |
|
NCBI chrNW_004624734:36,086,831...36,090,180
Ensembl chrNW_004624734:36,086,902...36,089,855
|
|
G |
Habp2 |
hyaluronan binding protein 2 |
treatment |
ISO |
associated with Thyroid Neoplasms |
RGD |
PMID:22715430 |
RGD:11353856 |
NCBI chrNW_004624737:32,963,943...32,997,789
Ensembl chrNW_004624737:32,964,406...32,995,110
|
|
G |
Havcr2 |
hepatitis A virus cellular receptor 2 |
disease_progression |
ISO |
DNA:polymorphisms: : +4259T>G (human) |
RGD |
PMID:22472081 |
RGD:7245505 |
NCBI chrNW_004624733:32,521,318...32,527,499
|
|
G |
Hdac3 |
histone deacetylase 3 |
|
ISO |
associated with Anaphylaxis; CTD Direct Evidence: marker/mechanism |
RGD CTD |
PMID:24619412 PMID:34973135 |
RGD:9590165 |
NCBI chrNW_004624774:845,970...864,080
Ensembl chrNW_004624774:845,358...863,809
|
|
G |
Hgf |
hepatocyte growth factor |
|
ISO |
CTD Direct Evidence: marker/mechanism associated with Mammary Neoplasms, Experimental; associated with Melanoma; associated with Pancreatic Neoplasms |
CTD RGD |
PMID:10688652 PMID:11893931 PMID:16459153 PMID:25971889 |
RGD:2317904 RGD:8548538 RGD:8548625 |
NCBI chrNW_004624739:30,233,589...30,307,508
Ensembl chrNW_004624739:30,236,146...30,307,356
|
|
G |
Hpse |
heparanase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22240343 |
|
NCBI chrNW_004624900:296,626...335,624
Ensembl chrNW_004624900:296,676...335,570
|
|
G |
Hrh2 |
histamine receptor H2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:6224980 |
|
NCBI chrNW_004624733:14,261,799...14,308,320
Ensembl chrNW_004624733:14,260,720...14,308,217
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20562527 |
|
NCBI chrNW_004624734:2,233,932...2,239,687
Ensembl chrNW_004624734:2,233,547...2,241,436
|
|
G |
Ibsp |
integrin binding sialoprotein |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22407340 PMID:24980816 |
|
NCBI chrNW_004624872:4,324,812...4,333,080
Ensembl chrNW_004624872:4,322,330...4,333,080
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
|
ISO |
associated with Melanoma, Cutaneous Malignant associated with Pancreatic Neoplasms;protein:increased expression:serum |
RGD |
PMID:10465581 PMID:12923961 |
RGD:2325163 RGD:8547593 |
NCBI chrNW_004624828:2,432,584...2,451,997
Ensembl chrNW_004624828:2,432,550...2,453,071
|
|
G |
Id1 |
inhibitor of DNA binding 1, HLH protein |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:24910342 |
|
NCBI chrNW_004624741:897,038...898,249
Ensembl chrNW_004624741:896,932...898,343
|
|
G |
Igf1 |
insulin like growth factor 1 |
|
ISO |
associated with Pancreatic Neoplasms CTD Direct Evidence: marker/mechanism associated with Uveal Melanoma;protein:increased expression:serum: |
RGD CTD |
PMID:18398872 PMID:19375852 PMID:23197685 |
RGD:2317643 RGD:8548834 |
NCBI chrNW_004624750:5,881,065...5,954,799
Ensembl chrNW_004624750:5,881,091...5,952,300
|
|
G |
Igf1r |
insulin like growth factor 1 receptor |
|
ISO |
associated with Pancreatic Neoplasms |
RGD |
PMID:16575403 |
RGD:2317645 |
NCBI chrNW_004624768:5,396,027...5,688,435
Ensembl chrNW_004624768:5,396,156...5,681,809
|
|
G |
Igf2 |
insulin like growth factor 2 |
|
ISO |
associated with Arthritis, Experimental; protein:increased expression:lung, bone, serum: |
RGD |
PMID:21859454 |
RGD:5510000 |
NCBI chrNW_004624767:14,969,977...14,997,577
Ensembl chrNW_004624767:14,969,866...14,979,026
|
|
G |
Ikzf1 |
IKAROS family zinc finger 1 |
|
ISO |
associated with colorectal cancer;DNA:polymorphisms: |
RGD |
PMID:31320627 |
RGD:150540328 |
NCBI chrNW_004624740:3,785,342...3,875,892
Ensembl chrNW_004624740:3,785,209...3,875,841
|
|
G |
Il10 |
interleukin 10 |
|
ISO |
|
RGD |
PMID:16035616 |
RGD:1598627 |
NCBI chrNW_004624807:4,687,249...4,691,658
Ensembl chrNW_004624807:4,687,176...4,691,732
|
|
G |
Il18 |
interleukin 18 |
|
ISO |
associated with breast cancer;protein:increased expression:serum CTD Direct Evidence: marker/mechanism associated with breast cancer;DNA:SNP:promoter:-137G>C (rs187238) (human) |
RGD CTD |
PMID:11215816 PMID:12209760 PMID:12748951 PMID:19152241 |
RGD:4889862 RGD:8655866 RGD:8655899 |
NCBI chrNW_004624784:7,294,286...7,312,959
Ensembl chrNW_004624784:7,294,183...7,304,687
|
|
G |
Il2 |
interleukin 2 |
treatment |
ISO |
associated with melanoma CTD Direct Evidence: therapeutic associated with melanoma; associated with neuroblastoma. |
RGD CTD |
PMID:8610104 PMID:8642346 PMID:9362156 PMID:17105418 |
RGD:14747043 RGD:14865005 RGD:8663438 |
NCBI chrNW_004624777:2,885,537...2,890,453
Ensembl chrNW_004624777:2,885,535...2,890,453
|
|
G |
Il6 |
interleukin 6 |
treatment |
ISO |
associated with stomach cancer, human cells in mouse model CTD Direct Evidence: marker/mechanism |
RGD CTD |
PMID:21937440 PMID:26101800 PMID:28186964 |
RGD:127229952 |
NCBI chrNW_004624739:7,957,709...7,963,414
Ensembl chrNW_004624739:7,957,674...7,962,318
|
|
G |
Itga6 |
integrin subunit alpha 6 |
|
ISO |
|
RGD |
PMID:13130099 |
RGD:1302259 |
NCBI chrNW_004624787:9,821,802...9,903,851
Ensembl chrNW_004624787:9,821,769...9,904,679
|
|
G |
Itgb1 |
integrin subunit beta 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:23562787 |
|
NCBI chrNW_004624805:8,748,848...8,800,259
Ensembl chrNW_004624805:8,765,949...8,802,149
|
|
G |
Itgb3 |
integrin subunit beta 3 |
|
ISO |
mRNA, protein:increased expression:lung associated with renal cell carcinoma;DNA:missense mutation:cds:p.L33P (human) |
RGD |
PMID:16831169 PMID:21107114 |
RGD:5037225 RGD:6907406 |
NCBI chrNW_004624849:1,895,378...1,952,755
Ensembl chrNW_004624849:1,895,914...1,952,665
|
|
G |
Jak2 |
Janus kinase 2 |
treatment |
ISO |
associated with stomach cancer, human cells in mouse model |
RGD |
PMID:28186964 |
RGD:127229952 |
NCBI chrNW_004624736:9,724,876...9,827,364
Ensembl chrNW_004624736:9,724,369...9,830,365
|
|
G |
Jup |
junction plakoglobin |
|
ISO |
associated with Ovarian Neoplasms |
RGD |
PMID:15619205 |
RGD:2301746 |
NCBI chrNW_004624795:1,954,733...1,972,080
Ensembl chrNW_004624795:1,954,290...1,975,018
|
|
G |
Kdm6a |
lysine demethylase 6A |
disease_progression |
ISO |
associated with lung adenocarcinoma;protein:increased expression:brain (human) |
RGD |
PMID:33291558 |
RGD:150429741 |
NCBI chrNW_004624887:1,065,173...1,279,660
Ensembl chrNW_004624887:1,065,883...1,279,186
|
|
G |
Kdr |
kinase insert domain receptor |
|
ISO |
associated with Carcinoma, Renal Cell |
RGD |
PMID:17465216 |
RGD:2301757 |
NCBI chrNW_004624761:14,330,224...14,380,680
Ensembl chrNW_004624761:14,330,489...14,379,051
|
|
G |
Kif2c |
kinesin family member 2C |
disease_progression |
ISO |
associated with colorectal cancer |
RGD |
PMID:18506187 |
RGD:27372891 |
NCBI chrNW_004624906:633,635...660,149
Ensembl chrNW_004624906:633,754...660,254
|
|
G |
Kiss1 |
KiSS-1 metastasis suppressor |
|
ISO |
associated with Ovarian Neoplasms |
RGD |
PMID:16283480 |
RGD:2298668 |
NCBI chrNW_004624807:6,800,144...6,805,555
Ensembl chrNW_004624807:6,803,265...6,805,433
|
|
G |
Kmt2b |
lysine methyltransferase 2B |
|
ISO |
associated with lung adenocarcinoma |
RGD |
PMID:33291558 |
RGD:150429741 |
NCBI chrNW_004624794:10,023,229...10,046,128
Ensembl chrNW_004624794:10,023,492...10,045,820
|
|
G |
Kmt2d |
lysine methyltransferase 2D |
disease_progression |
ISO |
associated with colorectal cancer;DNA:mutations:: |
RGD |
PMID:27875625 |
RGD:155582219 |
NCBI chrNW_004624816:3,129,127...3,169,143
Ensembl chrNW_004624816:3,133,659...3,166,346
|
|
G |
Kras |
KRAS proto-oncogene, GTPase |
treatment disease_progression |
ISO |
CTD Direct Evidence: marker/mechanism associated with colorectal cancer; DNA:mutation:cds: associated with stomach cancer; human cells in mouse model associated with Fibrosarcoma;mRNA,protein:decreased expression:: associated with colorectal cancer;DNA:mutations: : associated with colorectal cancer;DNA:mutation: : |
CTD RGD |
PMID:3552201 PMID:8635384 PMID:26210240 PMID:27264476 PMID:27431311 PMID:29032374 More...
|
RGD:11086960 RGD:11570402 RGD:14398745 RGD:14398751 RGD:152995400 |
NCBI chrNW_004624752:13,809,741...13,847,020
Ensembl chrNW_004624752:13,809,775...13,844,166
|
|
G |
L1cam |
L1 cell adhesion molecule |
treatment |
ISO |
associated with Lung Neoplasms; associated with Pancreatic Neoplasms; |
RGD |
PMID:22095073 PMID:22307136 |
RGD:11570404 RGD:11570503 |
NCBI chrNW_004624946:512,413...533,669
Ensembl chrNW_004624946:513,297...525,009
|
|
G |
Lamc2 |
laminin subunit gamma 2 |
|
ISO |
associated with lung adenocarcinoma; |
RGD |
PMID:25591736 |
RGD:11075980 |
NCBI chrNW_004624814:10,475,629...10,536,694
Ensembl chrNW_004624814:10,476,323...10,536,724
|
|
G |
Lect2 |
leukocyte cell derived chemotaxin 2 |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:30453282 |
|
NCBI chrNW_004624733:11,158,202...11,169,912
Ensembl chrNW_004624733:11,157,690...11,169,912
|
|
G |
Lef1 |
lymphoid enhancer binding factor 1 |
|
ISO |
associated with prostate cancer CTD Direct Evidence: marker/mechanism |
RGD CTD |
PMID:27067790 PMID:27811057 |
RGD:11531513 |
NCBI chrNW_004624830:1,320,034...1,422,774
Ensembl chrNW_004624830:1,321,387...1,424,389
|
|
G |
Lgals3 |
galectin 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:25882088 |
|
NCBI chrNW_004624731:14,300,138...14,307,843
Ensembl chrNW_004624731:14,298,201...14,304,637
|
|
G |
Llgl2 |
LLGL scribble cell polarity complex component 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28114269 |
|
NCBI chrNW_004624801:5,329,988...5,376,368
Ensembl chrNW_004624801:5,329,916...5,370,345
|
|
G |
LOC101702005 |
aromatase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28112739 |
|
NCBI chrNW_004624731:9,053,644...9,100,212
Ensembl chrNW_004624731:9,053,803...9,100,212
|
|
G |
Ly96 |
lymphocyte antigen 96 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22180778 |
|
NCBI chrNW_004624744:17,209,285...17,241,347
Ensembl chrNW_004624744:17,208,990...17,241,347
|
|
G |
Macc1 |
MET transcriptional regulator MACC1 |
treatment |
ISO |
associated with stomach cancer; human cells in mouse model CTD Direct Evidence: marker/mechanism |
RGD CTD |
PMID:27431311 PMID:36008464 |
RGD:152995400 |
NCBI chrNW_004624739:10,387,745...10,467,384
Ensembl chrNW_004624739:10,435,761...10,467,543
|
|
G |
Map2k4 |
mitogen-activated protein kinase kinase 4 |
disease_progression |
ISO |
associated with oral squamous cell carcinoma;mRNA, protein:increased expression:lymph node (human) |
RGD |
PMID:22165133 |
RGD:150429749 |
NCBI chrNW_004624786:14,457,382...14,597,027
Ensembl chrNW_004624786:14,457,452...14,597,027
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
treatment |
ISO |
CTD Direct Evidence: marker/mechanism associated with prostate adenocarcinoma |
CTD RGD |
PMID:22139534 PMID:22580338 |
RGD:13504820 |
NCBI chrNW_004624747:1,296,062...1,389,674
Ensembl chrNW_004624747:1,296,221...1,389,757
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22580338 |
|
NCBI chrNW_004624782:13,150,824...13,158,327
Ensembl chrNW_004624782:13,152,039...13,159,113
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
|
ISO |
associated with Colorectal Neoplasms CTD Direct Evidence: therapeutic |
RGD CTD |
PMID:21779479 PMID:25205654 |
RGD:13217416 |
NCBI chrNW_004624733:42,998,948...43,048,392
Ensembl chrNW_004624733:42,999,339...43,048,285
|
|
G |
Med28 |
mediator complex subunit 28 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21942447 |
|
NCBI chrNW_004624755:14,225,597...14,236,814
Ensembl chrNW_004624755:14,227,819...14,236,775
|
|
G |
Met |
MET proto-oncogene, receptor tyrosine kinase |
disease_progression |
ISO |
associated with Squamous Cell Carcinoma of the Tongue; CTD Direct Evidence: marker/mechanism |
RGD CTD |
PMID:20080979 PMID:21225626 PMID:22704061 |
RGD:8548616 |
NCBI chrNW_004624827:2,589,157...2,724,065
Ensembl chrNW_004624827:2,587,966...2,723,995
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
|
ISO |
associated with Pancreatic Neoplasms |
RGD |
PMID:20388395 |
RGD:2317702 |
NCBI chrNW_004624737:18,935,686...18,963,907
|
|
G |
Mlh1 |
mutL homolog 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17717427 |
|
NCBI chrNW_004624788:15,110,436...15,160,462
Ensembl chrNW_004624788:15,110,658...15,160,535
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:12538496 PMID:19487542 PMID:22580338 PMID:23548910 |
|
NCBI chrNW_004624878:71,642...79,660
Ensembl chrNW_004624878:71,642...79,602
|
|
G |
Mmp10 |
matrix metallopeptidase 10 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22022614 |
|
NCBI chrNW_004624878:107,330...117,654
Ensembl chrNW_004624878:107,361...117,459
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
|
ISO |
associated with Carcinoma, Renal Cell;mRNA, protein:increased expression:bone |
RGD |
PMID:18709334 |
RGD:2306080 |
NCBI chrNW_004624918:2,228,688...2,239,852
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
disease_progression |
ISO |
associated with pancreatic cancer; protein:increased expression, increased activity:pancreas CTD Direct Evidence: marker/mechanism associated with Gallbladder Neoplasms; protein:increased expression:gallbladder associated with Mammary Neoplasms, Animal;protein:increased expression:brain |
RGD CTD |
PMID:12173379 PMID:16158251 PMID:16475674 PMID:18398872 PMID:18665467 PMID:21209944 PMID:22321834 PMID:23707804 PMID:30603057 More...
|
RGD:2325743 RGD:2325749 RGD:8547884 |
NCBI chrNW_004624757:1,450,680...1,479,160
Ensembl chrNW_004624757:1,448,698...1,479,255
|
|
G |
Mmp24 |
matrix metallopeptidase 24 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27869830 |
|
NCBI chrNW_004624842:4,133,323...4,159,501
Ensembl chrNW_004624842:4,131,523...4,160,134
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
|
ISO |
associated with Mammary Neoplasms, Animal;protein:increased expression:brain |
RGD |
PMID:16158251 |
RGD:8547884 |
NCBI chrNW_004624878:39,282...47,386
Ensembl chrNW_004624878:39,358...47,075
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
disease_progression severity |
ISO |
associated with Mammary Neoplasms, Animal associated with Melanoma associated with carcinoma, pancreatic ductal; protein:increased expression:pancreas associated with osteosarcoma;protein:increased expression:bone (human) CTD Direct Evidence: marker/mechanism associated with Mammary Neoplasms, Animal;protein:increased expression:brain associated with Mammary Neoplasms, Animal; associated with Arthritis, Experimental associated with skin melanoma;DNA:missense mutation:cds:p.Q279R (human) associated with pancreatic cancer; protein:increased expression, increased activity:pancreas |
RGD CTD |
PMID:8912869 PMID:12173379 PMID:15659795 PMID:16033831 PMID:16158251 PMID:16475674 PMID:17346338 PMID:17378244 PMID:18676849 PMID:18930813 PMID:21209944 PMID:21859454 PMID:21942447 PMID:26546437 PMID:34626302 More...
|
RGD:152023746 RGD:2325749 RGD:2325855 RGD:5510000 RGD:8547861 RGD:8547878 RGD:8547884 RGD:8547886 RGD:8547928 |
NCBI chrNW_004624790:8,584,399...8,591,763
Ensembl chrNW_004624790:8,583,457...8,591,713
|
|
G |
Msh2 |
mutS homolog 2 |
|
ISO |
associated with Breast Neoplasms |
RGD |
PMID:17390069 |
RGD:2293506 |
NCBI chrNW_004624738:28,780,596...28,861,523
Ensembl chrNW_004624738:28,780,614...28,861,704
|
|
G |
Mst1 |
macrophage stimulating 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28114269 |
|
NCBI chrNW_004624730:3,612,467...3,617,257
Ensembl chrNW_004624730:3,610,241...3,617,530
|
|
G |
Mtdh |
metadherin |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:19111877 |
|
NCBI chrNW_004624763:4,905,261...4,967,014
Ensembl chrNW_004624763:4,905,044...4,967,014
|
|
G |
Mthfr |
methylenetetrahydrofolate reductase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17704422 |
|
NCBI chrNW_004624818:1,184,736...1,202,708
Ensembl chrNW_004624818:1,187,869...1,199,168
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
|
ISO |
associated with Pancreatic Neoplasms |
RGD |
PMID:23149918 |
RGD:10040959 |
NCBI chrNW_004624818:1,570,155...1,698,264
Ensembl chrNW_004624818:1,570,276...1,698,259
|
|
G |
Muc1 |
mucin 1, cell surface associated |
disease_progression |
ISO |
associated with Pancreatic Neoplasms associated with Carcinoma, Renal Cell; |
RGD |
PMID:10390012 PMID:12941828 PMID:16707592 |
RGD:2324648 RGD:2324652 RGD:7245968 |
NCBI chrNW_004624885:2,339,281...2,343,351
|
|
G |
Muc4 |
mucin 4, cell surface associated |
|
ISO |
associated with Melanoma |
RGD |
PMID:10918186 |
RGD:2303746 |
NCBI chrNW_004624730:61,153,753...61,176,859
|
|
G |
Muc5ac |
mucin 5AC, oligomeric mucus/gel-forming |
|
ISO |
associated with chloangiocarcinoma;protein:increased expression:bile duct |
RGD |
PMID:16124042 |
RGD:2324987 |
NCBI chrNW_004624766:21,439,023...21,461,108
|
|
G |
Muc6 |
mucin 6, oligomeric mucus/gel-forming |
disease_progression |
ISO |
associated with cholangiocarcinoma |
RGD |
PMID:18410610 |
RGD:2325159 |
NCBI chrNW_004624766:21,549,201...21,566,976
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22321834 |
|
NCBI chrNW_004624735:27,780,338...27,784,714
Ensembl chrNW_004624735:27,780,037...27,784,806
|
|
G |
Mylk |
myosin light chain kinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:12970723 PMID:18710790 |
|
NCBI chrNW_004624912:1,952,053...2,213,196
Ensembl chrNW_004624912:1,953,838...2,172,561
|
|
G |
Nagk |
N-acetylglucosamine kinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17085005 |
|
NCBI chrNW_004624762:2,382,708...2,391,896
Ensembl chrNW_004624762:2,382,709...2,391,656
|
|
G |
Ncoa1 |
nuclear receptor coactivator 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21080969 |
|
NCBI chrNW_004624738:6,770,745...7,054,616
Ensembl chrNW_004624738:6,943,726...7,054,454
|
|
G |
Ndc80 |
NDC80 kinetochore complex component |
disease_progression |
ISO |
associated with melanoma |
RGD |
PMID:31173190 |
RGD:40822820 |
NCBI chrNW_004624770:12,937,887...12,974,352
Ensembl chrNW_004624770:12,939,763...12,974,162
|
|
G |
Ndrg1 |
N-myc downstream regulated 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism|therapeutic |
CTD |
PMID:15867226 PMID:22972152 |
|
NCBI chrNW_004624735:22,734,365...22,782,247
Ensembl chrNW_004624735:22,734,228...22,782,347
|
|
G |
Nectin2 |
nectin cell adhesion molecule 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:29321541 |
|
NCBI chrNW_004624907:1,713,786...1,739,158
Ensembl chrNW_004624907:1,713,443...1,740,627
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:32682831 |
|
NCBI chrNW_004624787:14,355,330...14,381,353
Ensembl chrNW_004624787:14,355,791...14,381,251
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
|
ISO |
associated with prostate cancer |
RGD |
PMID:17974971 |
RGD:13506764 |
NCBI chrNW_004624830:5,334,273...5,430,887
Ensembl chrNW_004624830:5,333,616...5,408,723
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
|
ISO |
associated with prostate cancer;protein:increased serine phosphorylation |
RGD |
PMID:23093296 |
RGD:13506767 |
NCBI chrNW_004624838:1,384,337...1,387,602
Ensembl chrNW_004624838:1,384,204...1,390,205
|
|
G |
Nos2 |
nitric oxide synthase 2 |
disease_progression |
ISO |
associated with Carcinoma, Pancreatic Ductal associated with Carcinoma, Pancreatic Ductal; protein:increased expression:pancreas associated with Gallbladder Neoplasms: protein:increased expression:gallbladder |
RGD |
PMID:12660813 PMID:14991947 PMID:15222037 |
RGD:2325242 RGD:2325250 RGD:2325254 |
NCBI chrNW_004624786:491,944...530,427
Ensembl chrNW_004624786:489,311...528,271
|
|
G |
Nos3 |
nitric oxide synthase 3 |
susceptibility |
ISO |
protein:increased expression:blood vessel endothelial cell associated with Prostatic Neoplasms;DNA:polymorphism associated with Breast Neoplasms;DNA:polymorphism:promoter:-786T>C (human) |
RGD |
PMID:12445681 PMID:14623178 PMID:14672505 |
RGD:2292080 RGD:2292081 RGD:2292087 |
NCBI chrNW_004624800:5,600,215...5,619,020
Ensembl chrNW_004624800:5,600,212...5,619,004
|
|
G |
Nppa |
natriuretic peptide A |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:18717826 |
|
NCBI chrNW_004624818:1,147,654...1,149,722
Ensembl chrNW_004624818:1,147,974...1,148,927
|
|
G |
Nsun6 |
NOP2/Sun RNA methyltransferase 6 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28114269 |
|
NCBI chrNW_004624796:9,433,005...9,539,757
Ensembl chrNW_004624796:9,438,338...9,501,296
|
|
G |
Ogn |
osteoglycin |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17085005 |
|
NCBI chrNW_004624868:3,950,145...3,974,359
Ensembl chrNW_004624868:3,950,154...3,971,674
|
|
G |
Olig2 |
oligodendrocyte transcription factor 2 |
|
ISO |
associated with breast cancer |
RGD |
PMID:27340107 |
RGD:40902824 |
NCBI chrNW_004624745:21,270,804...21,274,225
Ensembl chrNW_004624745:21,270,965...21,272,932
|
|
G |
Orai1 |
ORAI calcium release-activated calcium modulator 1 |
treatment |
ISO |
associated with stomach cancer; human cells in mouse model |
RGD |
PMID:27431311 |
RGD:152995400 |
NCBI chrNW_004624747:22,071,373...22,085,180
Ensembl chrNW_004624747:22,071,404...22,085,976
|
|
G |
Osm |
oncostatin M |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21937440 |
|
NCBI chrNW_004624747:6,580,717...6,584,695
|
|
G |
Pcna |
proliferating cell nuclear antigen |
|
ISO |
associated with Seminoma |
RGD |
PMID:9143022 |
RGD:2315011 |
NCBI chrNW_004624741:6,143,584...6,148,055
Ensembl chrNW_004624741:6,143,332...6,148,898
|
|
G |
Pde5a |
phosphodiesterase 5A |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:12972520 |
|
NCBI chrNW_004624964:11,085...126,027
Ensembl chrNW_004624964:14,216...126,553
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
|
ISO |
associated with Breast Neoplasms;mRNA, protein:increased expression:breast |
RGD |
PMID:16596190 |
RGD:2292179 |
NCBI chrNW_004624752:9,072,471...9,088,289
Ensembl chrNW_004624752:9,072,512...9,088,593
|
|
G |
Pdgfrb |
platelet derived growth factor receptor beta |
|
ISO |
mRNA,protein:increased expression: : associated with Carcinoma, Renal Cell |
RGD |
PMID:14593398 PMID:15994946 |
RGD:13703041 RGD:2292198 |
NCBI chrNW_004624774:9,432,765...9,469,690
Ensembl chrNW_004624774:9,432,541...9,469,881
|
|
G |
Pebp1 |
phosphatidylethanolamine binding protein 1 |
|
ISO |
associated with Prostatic Neoplasms;protein:decreased expression: |
RGD |
PMID:12813171 |
RGD:2302862 |
NCBI chrNW_004624747:15,340,020...15,346,960
Ensembl chrNW_004624747:15,339,844...15,346,970
|
|
G |
Pik3c2b |
phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 beta |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21986133 |
|
NCBI chrNW_004624807:6,543,665...6,612,833
Ensembl chrNW_004624807:6,554,926...6,612,831
|
|
G |
Pik3ca |
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
treatment |
ISO |
associated with colorectal cancer;DNA:mutations:: CTD Direct Evidence: marker/mechanism |
RGD CTD |
PMID:23302486 PMID:29106415 |
RGD:14402409 |
NCBI chrNW_004624730:56,895,065...56,970,563
Ensembl chrNW_004624730:56,938,215...56,966,137
|
|
G |
Plau |
plasminogen activator, urokinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:16475674 |
|
NCBI chrNW_004624754:7,405,637...7,415,870
Ensembl chrNW_004624754:7,408,983...7,416,559
|
|
G |
Plaur |
plasminogen activator, urokinase receptor |
|
ISO |
CTD Direct Evidence: marker/mechanism associated with Ovarian Neoplasms |
CTD RGD |
PMID:15659795 PMID:22577342 |
RGD:6483788 |
NCBI chrNW_004624907:1,174,648...1,188,919
Ensembl chrNW_004624907:1,174,448...1,189,377
|
|
G |
Plod2 |
procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 |
ameliorates |
ISO |
associated with lung non-small cell carcinoma |
RGD |
PMID:29072684 |
RGD:151665822 |
NCBI chrNW_004624730:22,944,710...23,034,200
Ensembl chrNW_004624730:22,944,184...23,034,231
|
|
G |
Pml |
PML nuclear body scaffold |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:29335545 |
|
NCBI chrNW_004624781:464,858...498,146
Ensembl chrNW_004624781:464,658...497,775
|
|
G |
Pms2 |
PMS1 homolog 2, mismatch repair system component |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17717427 |
|
NCBI chrNW_004624740:31,315,121...31,345,137
|
|
G |
Ppia |
peptidylprolyl isomerase A |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21956400 |
|
NCBI chrNW_004624740:7,447,554...7,450,707
Ensembl chrNW_004624740:7,447,554...7,450,641
|
|
G |
Prnp |
prion protein (Kanno blood group) |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17387271 |
|
NCBI chrNW_004624741:5,785,139...5,802,162
Ensembl chrNW_004624741:5,785,158...5,802,162
|
|
G |
Prox1 |
prospero homeobox 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17415710 |
|
NCBI chrNW_004624771:19,188,543...19,238,621
Ensembl chrNW_004624771:19,196,366...19,233,338
|
|
G |
Prss8 |
serine protease 8 |
|
ISO |
associated with Prostatic Neoplasms;mRNA:decreased expression:prostate gland, bone |
RGD |
PMID:12518323 |
RGD:2292484 |
NCBI chrNW_004624782:14,169,204...14,177,137
Ensembl chrNW_004624782:14,169,866...14,173,676
|
|
G |
Ptch1 |
patched 1 |
|
ISO |
associated with colorectal cancer |
RGD |
PMID:20230186 |
RGD:150523835 |
NCBI chrNW_004624753:16,929,503...16,995,255
Ensembl chrNW_004624753:16,935,251...16,995,389
|
|
G |
Pten |
phosphatase and tensin homolog |
|
ISO |
associated with Mammary Neoplasms, Experimental CTD Direct Evidence: marker/mechanism |
RGD CTD |
PMID:10978354 PMID:18381417 |
RGD:2292496 |
NCBI chrNW_004624791:13,975,235...14,056,900
|
|
G |
Ptgis |
prostaglandin I2 synthase |
exacerbates |
ISO |
associated with colorectal cancer; protein:increased expression:colorectum (human) |
RGD |
PMID:22109564 |
RGD:151347833 |
NCBI chrNW_004624790:5,850,647...5,885,754
Ensembl chrNW_004624790:5,850,810...5,886,014
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
ISO |
associated with Breast Neoplasms associated with Mammary Neoplasms, Experimental CTD Direct Evidence: marker/mechanism associated with osteosarcoma; associated with breast neoplasm; associated with lung neoplasm |
RGD CTD |
PMID:16489006 PMID:18398660 PMID:18509974 PMID:18663571 PMID:18797196 PMID:19421193 PMID:21238650 More...
|
RGD:2300119 RGD:2300249 RGD:5135282 RGD:5135498 RGD:5135500 |
NCBI chrNW_004624814:6,897,818...6,904,890
Ensembl chrNW_004624814:6,897,857...6,903,728
|
|
G |
Ptk2 |
protein tyrosine kinase 2 |
|
ISO |
associated with Mammary Neoplasms, Experimental |
RGD |
PMID:15930288 PMID:16547501 |
RGD:2292557 RGD:2292560 |
NCBI chrNW_004624735:15,356,911...15,713,219
Ensembl chrNW_004624735:15,461,178...15,714,071
|
|
G |
Pxn |
paxillin |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:18492274 |
|
NCBI chrNW_004624747:13,371,128...13,435,619
Ensembl chrNW_004624747:13,370,243...13,435,714
|
|
G |
Rac1 |
Rac family small GTPase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:18506888 |
|
NCBI chrNW_004624740:30,912,841...30,933,882
Ensembl chrNW_004624740:30,911,598...30,934,025
|
|
G |
Rad52 |
RAD52 homolog, DNA repair protein |
susceptibility |
ISO |
associated with colorectal cancer; DNA:SNP:3'utr: (rs7963551) (human) |
RGD |
PMID:29245274 |
RGD:151361161 |
NCBI chrNW_004624735:9,123,599...9,153,373
|
|
G |
Ramp2 |
receptor activity modifying protein 2 |
|
ISO |
|
RGD |
PMID:31754214 |
RGD:152985691 |
NCBI chrNW_004624795:1,435,121...1,436,421
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27137931 |
|
NCBI chrNW_004624748:6,358,588...6,533,217
Ensembl chrNW_004624748:6,358,180...6,533,249
|
|
G |
Reck |
reversion inducing cysteine rich protein with kazal motifs |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17233834 |
|
NCBI chrNW_004624868:4,604,157...4,713,838
Ensembl chrNW_004624868:4,603,955...4,713,652
|
|
G |
Rhoa |
ras homolog family member A |
|
ISO |
associated with Ovarian Neoplasms |
RGD |
PMID:12808121 |
RGD:2298873 |
NCBI chrNW_004624730:3,316,122...3,361,820
|
|
G |
Rhoc |
ras homolog family member C |
|
ISO |
associated with Ovarian Neoplasms CTD Direct Evidence: marker/mechanism |
RGD CTD |
PMID:12808121 PMID:18230616 |
RGD:2298873 |
NCBI chrNW_004624772:8,481,826...8,487,530
Ensembl chrNW_004624772:8,479,015...8,486,171
|
|
G |
Rit1 |
Ras like without CAAX 1 |
ameliorates |
ISO |
associated with esophagus squamous cell carcinoma; human cells in mouse model |
RGD |
PMID:30348939 |
RGD:152999018 |
NCBI chrNW_004624885:1,275,765...1,284,613
|
|
G |
Ror1 |
receptor tyrosine kinase like orphan receptor 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28114269 |
|
NCBI chrNW_004624742:30,172,458...30,474,801
Ensembl chrNW_004624742:30,172,093...30,319,067
|
|
G |
Rps6ka3 |
ribosomal protein S6 kinase A3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21488662 |
|
NCBI chrNW_004624829:4,978,181...5,087,493
Ensembl chrNW_004624829:4,983,282...5,087,485
|
|
G |
Rxra |
retinoid X receptor alpha |
|
ISO |
associated with Prostatic Neoplasms |
RGD |
PMID:15318950 |
RGD:1643115 |
NCBI chrNW_004624760:2,379,809...2,455,749
Ensembl chrNW_004624760:2,380,708...2,456,928
|
|
G |
S100a4 |
S100 calcium binding protein A4 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21636539 PMID:21685359 PMID:36008464 |
|
NCBI chrNW_004624885:3,589,323...3,591,463
Ensembl chrNW_004624885:3,586,909...3,592,914
|
|
G |
Serpinb5 |
serpin family B member 5 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19514085 |
|
NCBI chrNW_004624792:9,196,932...9,220,147
Ensembl chrNW_004624792:9,198,657...9,221,264
|
|
G |
Serpinc1 |
serpin family C member 1 |
treatment |
ISO |
associated with Melanoma associated with Adenocarcinoma, Colon |
RGD |
PMID:16440418 |
RGD:1599327 |
NCBI chrNW_004624771:7,955,778...7,966,637
Ensembl chrNW_004624771:7,955,739...7,966,637
|
|
G |
Serpinf1 |
serpin family F member 1 |
|
ISO |
associated with Prostatic Neoplasms |
RGD |
PMID:15313905 |
RGD:2312355 |
NCBI chrNW_004624786:4,487,005...4,497,706
Ensembl chrNW_004624786:4,486,978...4,497,585
|
|
G |
Sirt1 |
sirtuin 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27793039 |
|
NCBI chrNW_004624754:2,304,476...2,332,705
Ensembl chrNW_004624754:2,304,634...2,330,946
|
|
G |
Six1 |
SIX homeobox 1 |
|
ISO |
human gene in a mouse model |
RGD |
PMID:23435380 |
RGD:11561950 |
NCBI chrNW_004624734:40,453,445...40,457,551
Ensembl chrNW_004624734:40,453,420...40,459,671
|
|
G |
Slc39a4 |
solute carrier family 39 member 4 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20957146 |
|
NCBI chrNW_004624735:12,433,024...12,438,406
Ensembl chrNW_004624735:12,434,169...12,438,510
|
|
G |
Slc39a6 |
solute carrier family 39 member 6 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:12839489 |
|
NCBI chrNW_004624779:10,400,581...10,433,405
Ensembl chrNW_004624779:10,399,198...10,432,869
|
|
G |
Slc3a2 |
solute carrier family 3 member 2 |
|
ISO |
|
RGD |
PMID:19018776 |
RGD:151361278 |
NCBI chrNW_004624926:1,301,866...1,314,598
Ensembl chrNW_004624926:1,301,584...1,315,707
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19015640 |
|
NCBI chrNW_004624777:18,540,006...18,619,881
Ensembl chrNW_004624777:18,546,799...18,619,947
|
|
G |
Slc7a5 |
solute carrier family 7 member 5 |
|
ISO |
|
RGD |
PMID:19018776 |
RGD:151361278 |
NCBI chrNW_004624746:1,325,368...1,349,616
|
|
G |
Smad4 |
SMAD family member 4 |
disease_progression |
ISO |
associated with colorectal carcinoma;DNA:mutation:cds: |
RGD |
PMID:10340381 |
RGD:21066333 |
NCBI chrNW_004624778:14,570,025...14,629,950
Ensembl chrNW_004624778:14,570,348...14,630,325
|
|
G |
Smo |
smoothened, frizzled class receptor |
|
ISO |
associated with colon cancer |
RGD |
PMID:23098507 |
RGD:150340555 |
NCBI chrNW_004624783:7,012,385...7,039,302
Ensembl chrNW_004624783:7,011,899...7,039,921
|
|
G |
Snai1 |
snail family transcriptional repressor 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22580338 PMID:23219715 |
|
NCBI chrNW_004624790:5,509,541...5,515,240
Ensembl chrNW_004624790:5,509,311...5,515,266
|
|
G |
Snai2 |
snail family transcriptional repressor 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22580338 |
|
NCBI chrNW_004624735:6,594,564...6,598,288
Ensembl chrNW_004624735:6,594,695...6,598,757
|
|
G |
Sncg |
synuclein gamma |
|
ISO |
DNA:hypomethylation: : protein:increased expression:breast |
RGD |
PMID:16140929 PMID:16821081 |
RGD:6478795 RGD:6478797 |
NCBI chrNW_004624841:192,396...196,568
Ensembl chrNW_004624841:192,398...196,064
|
|
G |
Sod2 |
superoxide dismutase 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:12538496 PMID:18930813 PMID:19487542 PMID:22580338 |
|
NCBI chrNW_004624855:3,260,800...3,271,864
Ensembl chrNW_004624855:3,260,809...3,271,367
|
|
G |
Sox30 |
SRY-box transcription factor 30 |
|
ISO |
associated with lung non-small cell carcinoma;mRNA, protein:decreased expression: : |
RGD |
PMID:29739711 |
| |